Version history

{
  "content_md": "# Prion Protein (PRNP)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Cellular Prion Protein (PrP)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[PRNP](/genes/prnp)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P04156\" target=\"_blank\">P04156</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>33-35 kDa (253 amino acids)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Family</td>\n    <td>Prion protein family</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Chromosome</td>\n    <td>20p13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Diseases</td>\n    <td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n# Cellular Prion Protein (PRNP)\n\n\n## Pathway / Mechanism Diagram\n\nflowchart TD\n    A[\"Gene<br/>Expression\"] --> B[\"Prion  (PRNP)<br/>Protein\"]\n    B --> C[\"Protein<br/>Folding and Structure\"]\n    C --> D[\"Biological<br/>Activity\"]\n    D --> E[\"Cellular<br/>Function\"]\n    F[\"Regulation/<br/>Modification\"] --> D\n    E --> G[\"Normal<br/>Physiology\"]\n    B -->|\"mutation\"| H[\"Pathological<br/>State\"]\n    H --> I[\"Disease<br/>Phenotype\"]\n\n\n## Introduction\n\nThe **cellular prion protein (PrP)**, encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].\n\nPrion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].\n\nBeyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].\n\n---\n\n## Structure and Biochemistry\n\n### Protein Architecture\n\nPrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:\n\n1. **N-terminal signal peptide (1-23 aa)**: Directs translocation to the endoplasmic reticulum\n2. **Flexible N-terminal domain (23-125 aa)**: Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)\n3. **Structured C-terminal domain (126-231 aa)**: Three α-helices and two β-strands forming a globular fold\n4. **GPI anchor signal (232-253 aa)**: Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment\n\n### Conformational States\n\nThe key property of PrP is its ability to adopt distinct conformational states:\n\n- **PrP^C (cellular)**: Predominantly α-helical, soluble, protease-sensitive, and non-infectious\n- **PrP^Sc (scrapie)**: Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation\n- **PrP^C** can be converted to **PrP^Sc** through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis\n\nThe structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].\n\n### Post-Translational Modifications\n\nPrP undergoes several important modifications:\n\n- **N-linked glycosylation** at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility\n- **Disulfide bond** between Cys179 and Cys214: Stabilizes the C-terminal globular domain\n- **GPI anchoring**: Targets PrP to lipid rafts in the plasma membrane\n- **Copper binding**: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity\n\n---\n\n## Normal Physiological Function\n\nDespite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:\n\n### Synaptic Function\n\nPrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:\n\n- Synaptic plasticity and long-term potentiation\n- Synaptic vesicle trafficking and neurotransmitter release\n- Maintenance of synaptic structure\n\n### Copper Homeostasis\n\nThe octapeptide repeat region binds copper ions with high affinity, suggesting a role in:\n\n- Cellular copper uptake and distribution\n- Antioxidant defense through copper-dependent enzymes\n- Modulation of synaptic copper signaling\n\n### Cell Signaling\n\nPrP interacts with multiple cell surface proteins and can:\n\n- Activate signaling cascades through various receptors\n- Interact with neural cell adhesion molecules\n- Modulate neuroprotective pathways\n\n### Neuroprotection\n\nPrP may provide neuroprotective effects through:\n\n- Anti-apoptotic signaling\n- Protection against oxidative stress\n- Regulation of autophagy\n\n---\n\n## Prion Diseases\n\n### Disease Spectrum\n\nPrion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:\n\n1. **Sporadic Creutzfeldt-Jakob Disease (sCJD)**: Most common form (~85% of cases), unknown etiology\n2. **Inherited Prion Diseases**: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion\n3. **Variant CJD (vCJD)**: Acquired from BSE-contaminated food products\n4. **Kuru**: Acquired through ritualistic cannibalism\n5. **Fatal Familial Insomnia (FFI)**: Characterized by progressive insomnia and autonomic dysfunction\n\n### Pathogenesis\n\nPrP^Sc accumulation in the brain leads to:\n\n- **Spongiform degeneration**: Vacuolation of brain tissue\n- **Neuronal loss**: Progressive death of neurons\n- **Gliosis**: Activation of astrocytes and microglia\n- **Amyloid plaque formation**: In some variants\n\nThe neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].\n\n### Genetic Susceptibility\n\nPolymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:\n\n- 129M/M: Predisposes to vCJD and certain CJD subtypes\n- 129V/V: Associated with longer incubation times\n- Heterozygosity may provide some protection\n\n---\n\n## Relationship to Alzheimer's Disease\n\nInteresting connections between PrP and AD have emerged [@Watts2014]:\n\n### PrP as an Aβ Receptor\n\nPrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:\n\n- Facilitate Aβ toxicity at synapses\n- Activate downstream signaling pathways\n- Contribute to early synaptic impairment in AD\n\n### Shared Mechanisms\n\nBoth prion diseases and AD involve:\n\n- Protein misfolding and aggregation\n- Synaptic loss\n- Progressive neurodegeneration\n- spreading through brain networks\n\n### Therapeutic Implications\n\nUnderstanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.\n\n### Molecular Mechanisms of PrP-Aβ Interaction\n\n**Binding Sites:**\n- The Aβ binding region on PrP is located in the N-terminal domain\n- Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding\n- The interaction is thought to be largely hydrophobic with some electrostatic components\n\n**Downstream Signaling:**\n- PrP-Aβ binding activates Fyn kinase\n- Leads to NMDA receptor phosphorylation\n- Results in excitotoxic calcium influx\n- Triggers downstream apoptotic pathways\n\n**Synaptic Effects:**\n- PrP mediates Aβ-induced synaptic spine loss\n- Impairs long-term potentiation (LTP)\n- Disrupts synaptic plasticity mechanisms\n- Contributes to early cognitive deficits\n\n### PrP in Other Neurodegenerative Diseases\n\n**Parkinson's Disease:**\n- PrP may interact with alpha-synuclein\n- Potential role in Lewy body formation\n- Possible influence on dopaminergic neuron survival\n\n**Huntington's Disease:**\n- PrP expression altered in HD models\n- May interact with mutant huntingtin\n- Potential contribution to synaptic dysfunction\n\n**Amyotrophic Lateral Sclerosis:**\n- PrP implicated in TDP-43 proteinopathy\n- Potential role in motor neuron vulnerability\n- May influence disease progression\n\n### PrP and Neuroinflammation\n\n**Microglial Activation:**\n- PrP can be released from neurons in exosomes\n- Extracellular PrP may activate microglia\n- Contributes to chronic neuroinflammation\n- Creates feedback loop promoting neurodegeneration\n\n**Cytokine Regulation:**\n- PrP influences cytokine production\n- Modulates inflammatory responses\n- May both promote and suppress inflammation depending on context\n\n**Blood-Brain Barrier:**\n- PrP affects BBB integrity\n- Dysregulation may allow peripheral immune cell entry\n- Contributes to neuroinflammatory processes\n\n### Cellular PrP Functions\n\n**Protein Quality Control:**\n- PrP interacts with cellular quality control machinery\n- May help target misfolded proteins for degradation\n- Loss of PrP function may impair protein clearance\n\n**Metal Ion Homeostasis:**\n- Copper binding is well-characterized\n- PrP may also bind other metal ions (zinc, iron)\n- Metal dyshomeostasis is implicated in multiple neurodegenerative diseases\n\n**Cell Adhesion:**\n- PrP functions as a cell adhesion molecule\n- Mediates cell-cell interactions at synapses\n- Influences neuronal connectivity during development\n\n### PrP in Aging and Cellular Senescence\n\n**Age-Related Changes:**\n- PrP expression changes with age\n- Oxidative modifications accumulate\n- May contribute to age-related neuronal vulnerability\n\n**Cellular Senescence:**\n- PrP may influence cellular senescence pathways\n- Senescent neurons show altered PrP expression\n- Could contribute to age-related neurodegeneration\n\n### PrP Spread and Propagation\n\n**Prion-Like Mechanisms:**\n- Aβ and tau can propagate via prion-like mechanisms\n- PrP may facilitate this spread\n- Template-driven misfolding in other proteins\n\n**Tissue-Specific Vulnerability:**\n- Neurons with high PrP expression are more vulnerable\n- Different brain regions show varying susceptibility\n- Regional PrP levels influence disease patterns\n\n### Biomarkers and Diagnostic Applications\n\n**Fluid Biomarkers:**\n- CSF PrP levels as potential biomarker\n- 14-3-3 protein in CSF for CJD diagnosis\n- Tau and neurofilament light chain measurements\n\n**Imaging Biomarkers:**\n- PET ligands for PrP aggregates\n- MRI for detecting spongiform changes\n- Diffusion tensor imaging for connectivity changes\n\n**Genetic Markers:**\n- PRNP polymorphisms modify disease risk\n- Codon 129 influences sporadic CJD\n- Octapeptide repeat number variations\n\n## Therapeutic Strategies\n\n### Current Approaches\n\nNo effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:\n\n1. **Anti-prion compounds**: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation\n2. **Immunotherapy**: Antibodies targeting PrP^Sc or preventing conversion\n3. **Gene silencing**: siRNA or antisense oligonucleotides to reduce PrP expression\n4. **Symptomatic treatment**: Managing cognitive and behavioral symptoms\n\n### Challenges\n\n- The blood-brain barrier limits drug delivery\n- PrP^Sc exists in multiple strains with distinct properties\n- Intervention must occur early in disease course\n- Need for reliable biomarkers to guide treatment\n- Heterogeneity of clinical presentations complicates diagnosis\n\n---\n\n## Specific Prion Disease Types\n\n### Sporadic Creutzfeldt-Jakob Disease (sCJD)\n\nsCJD represents approximately 85% of all human prion disease cases:\n\n**Epidemiology**\n- Incidence: 1-2 per million annually worldwide\n- Typically presents in individuals 50-70 years of age\n- Slight male predominance in some populations\n\n**Clinical Features**\n- Rapidly progressive dementia\n- Ataxia and cerebellar signs\n- Myoclonus (especially startle-induced)\n- Visual disturbances including cortical blindness\n- Pyramidal and extrapyramidal signs\n- Akinetic mutism in late stages\n\n**Subtypes**\n- MM1/MV1: Most common, rapid progression\n- VV2: Cerebellar predominant, slower progression\n- MM2: Longer disease duration\n\n**Diagnostic Features**\n- 14-3-3 protein in cerebrospinal fluid\n- Periodic sharp wave complexes on EEG\n- MRI hyperintensities in cortex and basal ganglia\n- Real-time quaking-induced conversion (RT-QuIC) positive\n\n### Variant Creutzfeldt-Jakob Disease (vCJD)\n\nvCJD results from exposure to bovine spongiform encephalopathy (BSE):\n\n**Epidemiology**\n- Linked to consumption of BSE-contaminated beef\n- First described in 1996 in the United Kingdom\n- Approximately 230 cases worldwide\n\n**Clinical Features**\n- Psychiatric symptoms at onset (depression, anxiety)\n- Behavioral changes and personality alterations\n- Sensory abnormalities including dysesthesia\n- Ataxia developing later in disease course\n- Progressive dementia\n- Longer survival than sCJD (median 14-18 months)\n\n**Pathological Features**\n- PrP amyloid plaques (florid plaques) throughout brain\n- PrP deposition in lymphoid tissues\n- Spongiform changes in basal ganglia and cerebellum\n\n### Fatal Familial Insomnia (FFI)\n\nFFI represents a unique prion disease with predominant sleep dysfunction:\n\n**Genetic Basis**\n- Caused by PRNP mutation D178N with methionine at codon 129\n- Autosomal dominant inheritance\n- Incomplete penetrance depending on codon 129 genotype\n\n**Clinical Features**\n- Progressive insomnia\n- Autonomic dysfunction (hyperhidrosis, hypertension)\n- Dysphagia and weight loss\n- Cognitive decline in later stages\n- Visual and auditory hallucinations\n\n**Neuropathology**\n- Selective thalamic degeneration, especially dorsomedial nucleus\n- Minimal spongiform change\n- PrP deposition in thalamus and inferior olive\n\n### Gerstmann-Sträussler-Scheinker Syndrome (GSS)\n\nGSS is a rare inherited prion disease:\n\n**Genetic Basis**\n- PRNP mutations including P102L, A117V, F198I, Q217R\n- Autosomal dominant inheritance\n- Variable age of onset (35-55 years typically)\n\n**Clinical Features**\n- Progressive ataxia\n- Dementia (later onset than ataxia)\n- Pyramidal signs\n- Extrapyramidal features in some subtypes\n- Disease duration: 2-10 years\n\n**Pathological Features**\n- PrP amyloid plaques throughout cerebellum and cerebral cortex\n- Multicentric plaque formation\n- Spongiform changes variable\n\n### Iatrogenic Prion Disease\n\nTransmission through medical procedures includes:\n\n**Sources of Transmission**\n- Dura mater grafts (historical)\n- Corneal transplants\n- Human growth hormone (historical)\n- Gonadotropin hormone\n- Blood transfusion (rare cases)\n\n**Clinical Features**\n- Similar to sCJD but longer incubation periods\n- For growth hormone cases: 5-20 year incubation\n- Typically rapid progression once symptomatic\n\n---\n\n## Cellular and Molecular Mechanisms\n\n### PrP^Sc Conversion Mechanism\n\nThe conversion of PrP^C to PrP^Sc involves:\n\n**Template-Directed Conversion**\n- PrP^Sc serves as template for conversion of PrP^C\n- Conformational information transfer through direct interaction\n- Heterodimer formation as intermediate\n\n**Nucleation-Dependent Polymerization**\n- PrP^Sc aggregates form through seeded polymerization\n- Lag phase followed by exponential growth\n- Fibril elongation through addition of monomers\n\n**Structural Transition**\n- Loss of α-helical content (from 40% to 20%)\n- Increase in β-sheet structure (from 10% to 40%)\n- Domain rearrangement in C-terminal region\n\n### PrP^Sc Strain Diversity\n\nPrion strains represent different conformations:\n\n**Strain Characteristics**\n- Distinct physicochemical properties\n- Different incubation periods in hosts\n- Variable neuropathology\n- Differential protease resistance patterns\n\n**Mechanisms of Strain Variation**\n- Different folding patterns of PrP^Sc\n- Variations in aggregation state\n- Distinct protofibril structures\n\n### Cellular Toxicity Pathways\n\nPrP^Sc causes neurotoxicity through multiple mechanisms:\n\n**ER Stress**\n- Accumulation of misfolded proteins triggers unfolded protein response\n- CHOP-mediated apoptosis\n- Disruption of calcium homeostasis\n\n**Oxidative Stress**\n- Mitochondrial dysfunction\n- Increased reactive oxygen species\n- Lipid peroxidation\n- DNA damage\n\n**Synaptic Dysfunction**\n- Loss of synaptic proteins\n- Impaired neurotransmitter release\n- Disruption of synaptic plasticity\n- Calcium dysregulation\n\n**Glial Activation**\n- Microglial activation and inflammation\n- Astrocyte reactivity\n- Cytokine release\n- Neuroinflammation amplification\n\n---\n\n## PrP and Other Neurodegenerative Diseases\n\n### PrP in Parkinson's Disease\n\nConnections between PrP and PD include:\n\n- PrP expression in dopaminergic neurons\n- Potential interaction with α-synuclein\n- Role in metal homeostasis relevant to PD\n- Possible common pathways in protein aggregation\n\n### PrP and Amyotrophic Lateral Sclerosis\n\nALS shares features with prion diseases:\n\n- PrP deposition in some ALS cases\n- Common mechanisms of protein aggregation\n- Overlapping pathways of cellular stress\n\n### Metal Ion Homeostasis\n\nPrP interacts with various metal ions:\n\n**Copper**\n- High affinity binding to octapeptide repeats\n- Role in copper uptake and distribution\n- Antioxidant function through SOD-like activity\n- Dyshomeostasis in prion disease\n\n**Iron**\n- PrP affects iron metabolism\n- Iron dysregulation in prion disease\n- Possible role in oxidative stress\n\n**Zinc**\n- PrP-zinc interactions\n- Potential signaling functions\n\n---\n\n## PrP as a Therapeutic Target\n\n### Immunotherapeutic Approaches\n\n**Active Immunization**\n- Vaccines targeting PrP^Sc\n- Generation of anti-PrP antibodies\n- Challenges: overcoming immune tolerance\n- Clinical trials in animal models\n\n**Passive Immunization**\n- Administration of anti-PrP monoclonal antibodies\n- Examples: 6D11, 8H4, Prioclone\n- Delivery challenges across blood-brain barrier\n\n### Small Molecule Inhibitors\n\n**Polyanionic Compounds**\n- Sulfated glycans inhibit PrP conversion\n- Pentosan polysulfate in clinical use\n- Limitations: poor BBB penetration\n\n**Tetracycline Derivatives**\n- Doxycycline shows anti-prion activity\n- Binding to PrP^Sc prevents aggregation\n- Clinical trials ongoing\n\n**Metal Chelators**\n- Cu/Zn chelation reduces conversion\n- Clioquinol trials in prion disease\n\n### Gene Silencing Approaches\n\n**Antisense Oligonucleotides**\n- Target PRNP mRNA\n- Reduce PrP^C expression\n- ASO trials in development\n- Advantages: specificity, distribution\n\n**RNAi Approaches**\n- siRNA targeting PRNP\n- Viral vector delivery\n- Challenges: efficient CNS delivery\n\n### Protein-Based Therapies\n\n**Dominant-Negative PrP**\n- Expression of mutant PrP that interferes with conversion\n- Competitive inhibition of PrP^Sc formation\n- Proof-of-concept in cell models\n\n**Chaperone-Based Approaches**\n- Heat shock proteins in PrP metabolism\n- Enhancement of PrP^C folding\n- Targeting protein quality control\n\n---\n\n## Diagnostic Biomarkers\n\n### Current Biomarkers\n\n**Cerebrospinal Fluid Markers**\n- 14-3-3 protein: sensitivity ~95%, specificity ~40%\n- Tau protein: elevated in some cases\n- Neurofilament light chain: promising marker\n\n**Real-Time Quaking-Induced Conversion (RT-QuIC)**\n- Sensitivity: 80-90% for sCJD\n- Specificity: >95%\n- Detects PrP^Sc seeding activity\n- Applied to CSF, olfactory epithelium, skin\n\n### Emerging Biomarkers\n\n**Blood-Based Markers**\n- PrP detection in plasma\n- Exosome-associated PrP^Sc\n- Sensitive detection methods in development\n\n**Imaging Biomarkers**\n- PET ligands for PrP^Sc\n- MRI advanced techniques\n- Diffusion tensor imaging\n\n---\n\n## Brain Atlas Resources\n\n- **Allen Human Brain Atlas**: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)\n- **Allen Mouse Brain Atlas**: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)\n- **BrainSpan Developmental Transcriptome**: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)\n\n### Clinical Trials and Emerging Therapies\n\n**Anti-Prion Compounds in Development:**\n- Polyanionic compounds that stabilize PrP^C\n- Small molecules targeting PrP^Sc formation\n- Natural products with anti-prion activity\n\n**Immunotherapy Approaches:**\n- Active immunization with PrP antigens\n- Passive monoclonal antibody administration\n- Antibody fragments for better brain penetration\n- CAR-T cell approaches for prion clearance\n\n**Gene Therapy Strategies:**\n- PRNP knockdown using RNAi approaches\n- CRISPR-based gene editing for correction\n- PRNP expression modulation\n- Viral vector-mediated delivery of anti-prion constructs\n\n**Combination Therapies:**\n- Antibody plus small molecule combinations\n- Gene therapy with pharmacological adjuncts\n- Multi-target approaches for maximum effect\n\n### Protein Dynamics and Misfolding\n\n**Folding Pathways:**\n- PrP folding occurs in the endoplasmic reticulum\n- Misfolding can occur at multiple stages\n- Quality control mechanisms normally prevent accumulation\n- Failure of quality control leads to disease\n\n**Aggregation Mechanisms:**\n- Nucleation-dependent polymerization\n- Formation of oligomeric intermediates\n- Amyloid fibril assembly\n- Strain variation through different conformations\n\n**Cellular Quality Control:**\n- ER-associated degradation (ERAD)\n- Autophagy-lysosome pathway\n- Proteasome-mediated degradation\n- Unfolded protein response activation\n\n### PrP in Prion Disease Subtypes\n\n**Sporadic CJD (sCJD):**\n- Most common form (~85% of cases)\n- No known genetic or infectious cause\n- Likely spontaneous PrP^Sc formation\n- Variable clinical presentation based on PRNP genotype\n\n**Variant CJD (vCJD):**\n- Acquired from BSE exposure\n- Younger age of onset than sCJD\n- Prominent psychiatric features\n- Long incubation period\n\n**Iatrogenic CJD:**\n- Transmission through medical procedures\n- corneal transplants, dura mater grafts\n- Contaminated human growth hormone\n- Blood transfusion transmission documented\n\n**Fatal Familial Insomnia (FFI):**\n- PRNP D178N mutation with methionine at codon 129\n- Primary insomnia with autonomic dysfunction\n- Selective thalamic degeneration\n- Distinct clinical phenotype from CJD\n\n### PrP Structural Biology\n\n**X-ray Crystallography:**\n- Detailed structure of C-terminal domain\n- Insight into helix-turn-helix arrangement\n- Domain organization in the structured region\n\n**NMR Studies:**\n- Dynamics of N-terminal domain\n- Flexible regions in physiological conditions\n- Conformational changes upon misfolding\n\n**Cryo-EM:**\n- Amyloid fibril structures\n- Different prion strain conformations\n- Polymorphic fibril architectures\n\n### PrP in Neurodevelopment\n\n**Developmental Expression:**\n- High expression during embryogenesis\n- Peak levels in early postnatal period\n- Sustained expression in adult brain\n- Cell type-specific patterns\n\n**Developmental Functions:**\n- Neuronal differentiation\n- Synapse formation\n- Myelination\n- Astrocyte maturation\n\n**Knockout Phenotypes:**\n- Relatively mild phenotype in Prnp-/- mice\n- Compensatory mechanisms exist\n- Subtle neurological deficits in specific contexts\n\n### Research Methods\n\n**Biochemical Approaches:**\n- Western blotting for PrP detection\n- ELISA for quantification\n- Pulse-chase experiments for trafficking\n- Proteomics for interaction mapping\n\n**Cell Biology:**\n- Cell culture models (neurons, astrocytes)\n- Primary neuronal cultures\n- Stem cell-derived neurons\n- Live cell imaging\n\n**Animal Models:**\n- Mouse models of prion disease\n- Transgenic mice expressing mutant PRNP\n- Knock-in models with human PRNP\n- Zebrafish models for development\n\n**Structural Methods:**\n- X-ray crystallography\n- NMR spectroscopy\n- Cryo-electron microscopy\n- Mass spectrometry\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Prion Diseases](/diseases/prion-diseases)\n- [PRNP Gene](/genes/prnp)\n- [Amyloid-beta Protein](/proteins/amyloid-beta)\n- [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)\n- [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)\n\n---\n\n## External Links\n\n- **UniProt**: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)\n- **AlphaFold**: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)\n- **OMIM**: [176640 - PRNP](https://omim.org/entry/176640)\n- **GeneCards**: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)\n- **PubMed**: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)\n- **Human Protein Atlas**: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)\n- **STRING Database**: [PrP interaction network](https://string-db.org/)\n\n### Prion Disease Surveillance and Public Health\n\n**Global Surveillance Networks:**\n- National CJD surveillance systems\n- WHO collaborative surveillance\n- Rapid alert systems for new variants\n\n**BSE and Food Safety:**\n- Cattle testing protocols\n- Feed restrictions and controls\n- Human exposure risk assessment\n\n**Infection Control:**\n- Sterilization protocols for surgical equipment\n- Blood donor screening\n- Tissue transplantation safety\n\n### PrP and Copper Metabolism Connection\n\n**Copper Binding Properties:**\n- High affinity binding to octapeptide repeats\n- Different affinity for Cu(I) and Cu(II)\n- Multiple binding sites per PrP molecule\n\n**Copper Transport:**\n- PrP may function as copper receptor\n- Facilitates copper uptake into cells\n- Participates in cellular copper distribution\n\n**Implications for Disease:**\n- Copper dyshomeostasis in prion disease\n- Potential therapeutic targeting of copper pathways\n- Interaction with other neurodegenerative processes\n\n### PrP and Zinc Metabolism\n\n**Zinc Binding:**\n- PrP can bind zinc ions\n- Different binding site than copper\n- Modulates PrP aggregation properties\n\n**Zinc Signaling:**\n- Important for synaptic function\n- PrP may regulate zinc availability\n- Implications for synaptic plasticity\n\n### PrP in Oligodendrocyte Function\n\n**Myelin Maintenance:**\n- PrP expressed in oligodendrocytes\n- Important for myelin integrity\n- Dysfunction may contribute to demyelination\n\n**White Matter Pathology:**\n- White matter changes in CJD\n- Potential for therapeutic intervention\n- Imaging biomarkers for progression\n\n### PrP in Astrocyte Function\n\n**Astrocyte Expression:**\n- PrP expressed in astrocytes\n- Functions in astrocyte-neuron communication\n- May influence neurovascular unit\n\n**Reactive Astrocytosis:**\n- Astrocyte activation in prion disease\n- Both protective and harmful roles\n- Potential therapeutic target\n\n### PrP and Blood-Brain Barrier\n\n**BBB Regulation:**\n- PrP influences BBB development\n- Maintains BBB integrity\n- Dysfunction allows peripheral access\n\n**Therapeutic Implications:**\n- Drug delivery challenges\n- Strategies to improve brain penetration\n- Engineering of therapeutic antibodies\n\n### Genetic Epidemiology\n\n**Population Studies:**\n- Allele frequency variations\n- Founder mutations in specific populations\n- Consanguinity effects on incidence\n\n**Genotype-Phenotype Correlations:**\n- 129 polymorphism effects\n- Mutation-specific clinical presentations\n- Modifier genes and modifiers\n\n### PrP in Veterinary Medicine\n\n**Animal Prion Diseases:**\n- Scrapie in sheep and goats\n- BSE in cattle\n- Chronic wasting disease in cervids\n- Feline spongiform encephalopathy\n\n**Zoonotic Potential:**\n- Species barrier studies\n- Cross-species transmission\n- Public health implications\n\n### Future Research Directions\n\n**Basic Science Priorities:**\n- Structural basis for strain variation\n- Molecular mechanisms of neurotoxicity\n- Early diagnostic markers\n\n**Clinical Priorities:**\n- Disease-modifying therapies\n- Biomarkers for clinical trials\n- Early intervention strategies\n\n**Therapeutic Priorities:**\n- Small molecule development\n- Antibody therapeutics\n- Gene therapy approaches\n- Combination therapies\n\n---\n\n## References\n\n1. [Linden, Biology of the prion protein (2024)](https://doi.org/10.1016/j.sbi.2024.101527)\n2. [Watzlawik, Prion protein: structure and function (2023)](https://doi.org/10.1016/bs.pmbts.2023.02.001)\n3. [Caughey, Prion protein conversions (2023)](https://doi.org/10.1038/s41579-022-00771-4)\n4. [Aguib, Prion protein therapeutics (2022)](https://doi.org/10.1038/s41582-022-00635-8)\n5. [Prusiner, Prions (2015)](https://doi.org/10.1073/pnas.1514714112)\n6. [Caughey, Prion protein conversion in vitro (2014)](https://doi.org/10.1016/j.jmb.2014.02.009)\n7. [Soto, Prions: the biological particles that transmit neurodegenerative diseases (2011)](https://doi.org/10.4161/pri.5.3.16574)\n8. [Collins, Molecular genetics of human prion diseases (2001)]([DOI:10.1016/S0361-9230(01)00643-2](https://doi.org/10.1016/S0361-9230(01)00643-2))\n9. [Colby, Prions: propagation and evolution (2010)](https://doi.org/10.1007/82_2010_106)\n10. [Caughey, Prions and their potential therapeutic targeting (2009)](https://doi.org/10.2741/3376)\n11. [Soto, Challenges for prion disease diagnostics (2010)](https://doi.org/10.1007/s00018-010-0270-5)\n12. [Belay, Human prion diseases (1999)](https://doi.org/10.1128/CMR.12.2.281)\n13. [Johnson, Therapeutic approaches to prion disease (2005)](https://doi.org/10.1385/1-59259-848-3:331)\n14. [Caughey, Trends in prion biology and disease (2011)](https://doi.org/10.1042/ETLS20170039)\n15. [Geschwind, Prion diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25634165/)\n16. [Zanusso, Prion protein structural features and pathological isoforms (2016)](https://pubmed.ncbi.nlm.nih.gov/27689081/)\n17. [Purro, Prions and synaptic dysfunction (2012)](https://doi.org/10.4161/pri.20245)\n18. [Watts, Prion protein and Alzheimer disease: the end of the beginning? (2014)]([DOI:10.1016/S1474-4422(14)70158-1](https://doi.org/10.1016/S1474-4422(14)70158-1))\n19. [Bellinger, Prions in the brain and neurodegenerative disease (2015)](https://doi.org/10.1007/s11064-015-1577-2)\n20. [Soto, Functional role of the cellular prion protein in health and disease (2013)](https://doi.org/10.2217/fnl.13.42)\n21. [Hill et al., Prion disease diagnosis and RT-QuIC (2023)](https://pubmed.ncbi.nlm.nih.gov/37015345/)\n22. [Chen et al., Prion protein and metal ion homeostasis (2022)](https://doi.org/10.1016/j.ccr.2022.214891)\n23. [Biasini et al., Cellular prion protein and neuronal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)",
  "entity_type": "protein"
}

{
  "content_md": "# Prion Protein (PRNP)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Cellular Prion Protein (PrP)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[PRNP](/genes/prnp)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P04156\" target=\"_blank\">P04156</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>33-35 kDa (253 amino acids)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Family</td>\n    <td>Prion protein family</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Chromosome</td>\n    <td>20p13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Diseases</td>\n    <td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n# Cellular Prion Protein (PRNP)\n\n\n## Pathway / Mechanism Diagram\n\n```mermaid\nflowchart TD\n    A[\"Gene<br/>Expression\"] --> B[\"Prion  (PRNP)<br/>Protein\"]\n    B --> C[\"Protein<br/>Folding and Structure\"]\n    C --> D[\"Biological<br/>Activity\"]\n    D --> E[\"Cellular<br/>Function\"]\n    F[\"Regulation/<br/>Modification\"] --> D\n    E --> G[\"Normal<br/>Physiology\"]\n    B -->|\"mutation\"| H[\"Pathological<br/>State\"]\n    H --> I[\"Disease<br/>Phenotype\"]\n```\n\n\n## Introduction\n\nThe **cellular prion protein (PrP)**, encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].\n\nPrion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].\n\nBeyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].\n\n---\n\n## Structure and Biochemistry\n\n### Protein Architecture\n\nPrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:\n\n1. **N-terminal signal peptide (1-23 aa)**: Directs translocation to the endoplasmic reticulum\n2. **Flexible N-terminal domain (23-125 aa)**: Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)\n3. **Structured C-terminal domain (126-231 aa)**: Three α-helices and two β-strands forming a globular fold\n4. **GPI anchor signal (232-253 aa)**: Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment\n\n### Conformational States\n\nThe key property of PrP is its ability to adopt distinct conformational states:\n\n- **PrP^C (cellular)**: Predominantly α-helical, soluble, protease-sensitive, and non-infectious\n- **PrP^Sc (scrapie)**: Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation\n- **PrP^C** can be converted to **PrP^Sc** through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis\n\nThe structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].\n\n### Post-Translational Modifications\n\nPrP undergoes several important modifications:\n\n- **N-linked glycosylation** at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility\n- **Disulfide bond** between Cys179 and Cys214: Stabilizes the C-terminal globular domain\n- **GPI anchoring**: Targets PrP to lipid rafts in the plasma membrane\n- **Copper binding**: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity\n\n---\n\n## Normal Physiological Function\n\nDespite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:\n\n### Synaptic Function\n\nPrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:\n\n- Synaptic plasticity and long-term potentiation\n- Synaptic vesicle trafficking and neurotransmitter release\n- Maintenance of synaptic structure\n\n### Copper Homeostasis\n\nThe octapeptide repeat region binds copper ions with high affinity, suggesting a role in:\n\n- Cellular copper uptake and distribution\n- Antioxidant defense through copper-dependent enzymes\n- Modulation of synaptic copper signaling\n\n### Cell Signaling\n\nPrP interacts with multiple cell surface proteins and can:\n\n- Activate signaling cascades through various receptors\n- Interact with neural cell adhesion molecules\n- Modulate neuroprotective pathways\n\n### Neuroprotection\n\nPrP may provide neuroprotective effects through:\n\n- Anti-apoptotic signaling\n- Protection against oxidative stress\n- Regulation of autophagy\n\n---\n\n## Prion Diseases\n\n### Disease Spectrum\n\nPrion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:\n\n1. **Sporadic Creutzfeldt-Jakob Disease (sCJD)**: Most common form (~85% of cases), unknown etiology\n2. **Inherited Prion Diseases**: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion\n3. **Variant CJD (vCJD)**: Acquired from BSE-contaminated food products\n4. **Kuru**: Acquired through ritualistic cannibalism\n5. **Fatal Familial Insomnia (FFI)**: Characterized by progressive insomnia and autonomic dysfunction\n\n### Pathogenesis\n\nPrP^Sc accumulation in the brain leads to:\n\n- **Spongiform degeneration**: Vacuolation of brain tissue\n- **Neuronal loss**: Progressive death of neurons\n- **Gliosis**: Activation of astrocytes and microglia\n- **Amyloid plaque formation**: In some variants\n\nThe neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].\n\n### Genetic Susceptibility\n\nPolymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:\n\n- 129M/M: Predisposes to vCJD and certain CJD subtypes\n- 129V/V: Associated with longer incubation times\n- Heterozygosity may provide some protection\n\n---\n\n## Relationship to Alzheimer's Disease\n\nInteresting connections between PrP and AD have emerged [@Watts2014]:\n\n### PrP as an Aβ Receptor\n\nPrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:\n\n- Facilitate Aβ toxicity at synapses\n- Activate downstream signaling pathways\n- Contribute to early synaptic impairment in AD\n\n### Shared Mechanisms\n\nBoth prion diseases and AD involve:\n\n- Protein misfolding and aggregation\n- Synaptic loss\n- Progressive neurodegeneration\n- spreading through brain networks\n\n### Therapeutic Implications\n\nUnderstanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.\n\n### Molecular Mechanisms of PrP-Aβ Interaction\n\n**Binding Sites:**\n- The Aβ binding region on PrP is located in the N-terminal domain\n- Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding\n- The interaction is thought to be largely hydrophobic with some electrostatic components\n\n**Downstream Signaling:**\n- PrP-Aβ binding activates Fyn kinase\n- Leads to NMDA receptor phosphorylation\n- Results in excitotoxic calcium influx\n- Triggers downstream apoptotic pathways\n\n**Synaptic Effects:**\n- PrP mediates Aβ-induced synaptic spine loss\n- Impairs long-term potentiation (LTP)\n- Disrupts synaptic plasticity mechanisms\n- Contributes to early cognitive deficits\n\n### PrP in Other Neurodegenerative Diseases\n\n**Parkinson's Disease:**\n- PrP may interact with alpha-synuclein\n- Potential role in Lewy body formation\n- Possible influence on dopaminergic neuron survival\n\n**Huntington's Disease:**\n- PrP expression altered in HD models\n- May interact with mutant huntingtin\n- Potential contribution to synaptic dysfunction\n\n**Amyotrophic Lateral Sclerosis:**\n- PrP implicated in TDP-43 proteinopathy\n- Potential role in motor neuron vulnerability\n- May influence disease progression\n\n### PrP and Neuroinflammation\n\n**Microglial Activation:**\n- PrP can be released from neurons in exosomes\n- Extracellular PrP may activate microglia\n- Contributes to chronic neuroinflammation\n- Creates feedback loop promoting neurodegeneration\n\n**Cytokine Regulation:**\n- PrP influences cytokine production\n- Modulates inflammatory responses\n- May both promote and suppress inflammation depending on context\n\n**Blood-Brain Barrier:**\n- PrP affects BBB integrity\n- Dysregulation may allow peripheral immune cell entry\n- Contributes to neuroinflammatory processes\n\n### Cellular PrP Functions\n\n**Protein Quality Control:**\n- PrP interacts with cellular quality control machinery\n- May help target misfolded proteins for degradation\n- Loss of PrP function may impair protein clearance\n\n**Metal Ion Homeostasis:**\n- Copper binding is well-characterized\n- PrP may also bind other metal ions (zinc, iron)\n- Metal dyshomeostasis is implicated in multiple neurodegenerative diseases\n\n**Cell Adhesion:**\n- PrP functions as a cell adhesion molecule\n- Mediates cell-cell interactions at synapses\n- Influences neuronal connectivity during development\n\n### PrP in Aging and Cellular Senescence\n\n**Age-Related Changes:**\n- PrP expression changes with age\n- Oxidative modifications accumulate\n- May contribute to age-related neuronal vulnerability\n\n**Cellular Senescence:**\n- PrP may influence cellular senescence pathways\n- Senescent neurons show altered PrP expression\n- Could contribute to age-related neurodegeneration\n\n### PrP Spread and Propagation\n\n**Prion-Like Mechanisms:**\n- Aβ and tau can propagate via prion-like mechanisms\n- PrP may facilitate this spread\n- Template-driven misfolding in other proteins\n\n**Tissue-Specific Vulnerability:**\n- Neurons with high PrP expression are more vulnerable\n- Different brain regions show varying susceptibility\n- Regional PrP levels influence disease patterns\n\n### Biomarkers and Diagnostic Applications\n\n**Fluid Biomarkers:**\n- CSF PrP levels as potential biomarker\n- 14-3-3 protein in CSF for CJD diagnosis\n- Tau and neurofilament light chain measurements\n\n**Imaging Biomarkers:**\n- PET ligands for PrP aggregates\n- MRI for detecting spongiform changes\n- Diffusion tensor imaging for connectivity changes\n\n**Genetic Markers:**\n- PRNP polymorphisms modify disease risk\n- Codon 129 influences sporadic CJD\n- Octapeptide repeat number variations\n\n## Therapeutic Strategies\n\n### Current Approaches\n\nNo effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:\n\n1. **Anti-prion compounds**: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation\n2. **Immunotherapy**: Antibodies targeting PrP^Sc or preventing conversion\n3. **Gene silencing**: siRNA or antisense oligonucleotides to reduce PrP expression\n4. **Symptomatic treatment**: Managing cognitive and behavioral symptoms\n\n### Challenges\n\n- The blood-brain barrier limits drug delivery\n- PrP^Sc exists in multiple strains with distinct properties\n- Intervention must occur early in disease course\n- Need for reliable biomarkers to guide treatment\n- Heterogeneity of clinical presentations complicates diagnosis\n\n---\n\n## Specific Prion Disease Types\n\n### Sporadic Creutzfeldt-Jakob Disease (sCJD)\n\nsCJD represents approximately 85% of all human prion disease cases:\n\n**Epidemiology**\n- Incidence: 1-2 per million annually worldwide\n- Typically presents in individuals 50-70 years of age\n- Slight male predominance in some populations\n\n**Clinical Features**\n- Rapidly progressive dementia\n- Ataxia and cerebellar signs\n- Myoclonus (especially startle-induced)\n- Visual disturbances including cortical blindness\n- Pyramidal and extrapyramidal signs\n- Akinetic mutism in late stages\n\n**Subtypes**\n- MM1/MV1: Most common, rapid progression\n- VV2: Cerebellar predominant, slower progression\n- MM2: Longer disease duration\n\n**Diagnostic Features**\n- 14-3-3 protein in cerebrospinal fluid\n- Periodic sharp wave complexes on EEG\n- MRI hyperintensities in cortex and basal ganglia\n- Real-time quaking-induced conversion (RT-QuIC) positive\n\n### Variant Creutzfeldt-Jakob Disease (vCJD)\n\nvCJD results from exposure to bovine spongiform encephalopathy (BSE):\n\n**Epidemiology**\n- Linked to consumption of BSE-contaminated beef\n- First described in 1996 in the United Kingdom\n- Approximately 230 cases worldwide\n\n**Clinical Features**\n- Psychiatric symptoms at onset (depression, anxiety)\n- Behavioral changes and personality alterations\n- Sensory abnormalities including dysesthesia\n- Ataxia developing later in disease course\n- Progressive dementia\n- Longer survival than sCJD (median 14-18 months)\n\n**Pathological Features**\n- PrP amyloid plaques (florid plaques) throughout brain\n- PrP deposition in lymphoid tissues\n- Spongiform changes in basal ganglia and cerebellum\n\n### Fatal Familial Insomnia (FFI)\n\nFFI represents a unique prion disease with predominant sleep dysfunction:\n\n**Genetic Basis**\n- Caused by PRNP mutation D178N with methionine at codon 129\n- Autosomal dominant inheritance\n- Incomplete penetrance depending on codon 129 genotype\n\n**Clinical Features**\n- Progressive insomnia\n- Autonomic dysfunction (hyperhidrosis, hypertension)\n- Dysphagia and weight loss\n- Cognitive decline in later stages\n- Visual and auditory hallucinations\n\n**Neuropathology**\n- Selective thalamic degeneration, especially dorsomedial nucleus\n- Minimal spongiform change\n- PrP deposition in thalamus and inferior olive\n\n### Gerstmann-Sträussler-Scheinker Syndrome (GSS)\n\nGSS is a rare inherited prion disease:\n\n**Genetic Basis**\n- PRNP mutations including P102L, A117V, F198I, Q217R\n- Autosomal dominant inheritance\n- Variable age of onset (35-55 years typically)\n\n**Clinical Features**\n- Progressive ataxia\n- Dementia (later onset than ataxia)\n- Pyramidal signs\n- Extrapyramidal features in some subtypes\n- Disease duration: 2-10 years\n\n**Pathological Features**\n- PrP amyloid plaques throughout cerebellum and cerebral cortex\n- Multicentric plaque formation\n- Spongiform changes variable\n\n### Iatrogenic Prion Disease\n\nTransmission through medical procedures includes:\n\n**Sources of Transmission**\n- Dura mater grafts (historical)\n- Corneal transplants\n- Human growth hormone (historical)\n- Gonadotropin hormone\n- Blood transfusion (rare cases)\n\n**Clinical Features**\n- Similar to sCJD but longer incubation periods\n- For growth hormone cases: 5-20 year incubation\n- Typically rapid progression once symptomatic\n\n---\n\n## Cellular and Molecular Mechanisms\n\n### PrP^Sc Conversion Mechanism\n\nThe conversion of PrP^C to PrP^Sc involves:\n\n**Template-Directed Conversion**\n- PrP^Sc serves as template for conversion of PrP^C\n- Conformational information transfer through direct interaction\n- Heterodimer formation as intermediate\n\n**Nucleation-Dependent Polymerization**\n- PrP^Sc aggregates form through seeded polymerization\n- Lag phase followed by exponential growth\n- Fibril elongation through addition of monomers\n\n**Structural Transition**\n- Loss of α-helical content (from 40% to 20%)\n- Increase in β-sheet structure (from 10% to 40%)\n- Domain rearrangement in C-terminal region\n\n### PrP^Sc Strain Diversity\n\nPrion strains represent different conformations:\n\n**Strain Characteristics**\n- Distinct physicochemical properties\n- Different incubation periods in hosts\n- Variable neuropathology\n- Differential protease resistance patterns\n\n**Mechanisms of Strain Variation**\n- Different folding patterns of PrP^Sc\n- Variations in aggregation state\n- Distinct protofibril structures\n\n### Cellular Toxicity Pathways\n\nPrP^Sc causes neurotoxicity through multiple mechanisms:\n\n**ER Stress**\n- Accumulation of misfolded proteins triggers unfolded protein response\n- CHOP-mediated apoptosis\n- Disruption of calcium homeostasis\n\n**Oxidative Stress**\n- Mitochondrial dysfunction\n- Increased reactive oxygen species\n- Lipid peroxidation\n- DNA damage\n\n**Synaptic Dysfunction**\n- Loss of synaptic proteins\n- Impaired neurotransmitter release\n- Disruption of synaptic plasticity\n- Calcium dysregulation\n\n**Glial Activation**\n- Microglial activation and inflammation\n- Astrocyte reactivity\n- Cytokine release\n- Neuroinflammation amplification\n\n---\n\n## PrP and Other Neurodegenerative Diseases\n\n### PrP in Parkinson's Disease\n\nConnections between PrP and PD include:\n\n- PrP expression in dopaminergic neurons\n- Potential interaction with α-synuclein\n- Role in metal homeostasis relevant to PD\n- Possible common pathways in protein aggregation\n\n### PrP and Amyotrophic Lateral Sclerosis\n\nALS shares features with prion diseases:\n\n- PrP deposition in some ALS cases\n- Common mechanisms of protein aggregation\n- Overlapping pathways of cellular stress\n\n### Metal Ion Homeostasis\n\nPrP interacts with various metal ions:\n\n**Copper**\n- High affinity binding to octapeptide repeats\n- Role in copper uptake and distribution\n- Antioxidant function through SOD-like activity\n- Dyshomeostasis in prion disease\n\n**Iron**\n- PrP affects iron metabolism\n- Iron dysregulation in prion disease\n- Possible role in oxidative stress\n\n**Zinc**\n- PrP-zinc interactions\n- Potential signaling functions\n\n---\n\n## PrP as a Therapeutic Target\n\n### Immunotherapeutic Approaches\n\n**Active Immunization**\n- Vaccines targeting PrP^Sc\n- Generation of anti-PrP antibodies\n- Challenges: overcoming immune tolerance\n- Clinical trials in animal models\n\n**Passive Immunization**\n- Administration of anti-PrP monoclonal antibodies\n- Examples: 6D11, 8H4, Prioclone\n- Delivery challenges across blood-brain barrier\n\n### Small Molecule Inhibitors\n\n**Polyanionic Compounds**\n- Sulfated glycans inhibit PrP conversion\n- Pentosan polysulfate in clinical use\n- Limitations: poor BBB penetration\n\n**Tetracycline Derivatives**\n- Doxycycline shows anti-prion activity\n- Binding to PrP^Sc prevents aggregation\n- Clinical trials ongoing\n\n**Metal Chelators**\n- Cu/Zn chelation reduces conversion\n- Clioquinol trials in prion disease\n\n### Gene Silencing Approaches\n\n**Antisense Oligonucleotides**\n- Target PRNP mRNA\n- Reduce PrP^C expression\n- ASO trials in development\n- Advantages: specificity, distribution\n\n**RNAi Approaches**\n- siRNA targeting PRNP\n- Viral vector delivery\n- Challenges: efficient CNS delivery\n\n### Protein-Based Therapies\n\n**Dominant-Negative PrP**\n- Expression of mutant PrP that interferes with conversion\n- Competitive inhibition of PrP^Sc formation\n- Proof-of-concept in cell models\n\n**Chaperone-Based Approaches**\n- Heat shock proteins in PrP metabolism\n- Enhancement of PrP^C folding\n- Targeting protein quality control\n\n---\n\n## Diagnostic Biomarkers\n\n### Current Biomarkers\n\n**Cerebrospinal Fluid Markers**\n- 14-3-3 protein: sensitivity ~95%, specificity ~40%\n- Tau protein: elevated in some cases\n- Neurofilament light chain: promising marker\n\n**Real-Time Quaking-Induced Conversion (RT-QuIC)**\n- Sensitivity: 80-90% for sCJD\n- Specificity: >95%\n- Detects PrP^Sc seeding activity\n- Applied to CSF, olfactory epithelium, skin\n\n### Emerging Biomarkers\n\n**Blood-Based Markers**\n- PrP detection in plasma\n- Exosome-associated PrP^Sc\n- Sensitive detection methods in development\n\n**Imaging Biomarkers**\n- PET ligands for PrP^Sc\n- MRI advanced techniques\n- Diffusion tensor imaging\n\n---\n\n## Brain Atlas Resources\n\n- **Allen Human Brain Atlas**: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)\n- **Allen Mouse Brain Atlas**: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)\n- **BrainSpan Developmental Transcriptome**: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)\n\n### Clinical Trials and Emerging Therapies\n\n**Anti-Prion Compounds in Development:**\n- Polyanionic compounds that stabilize PrP^C\n- Small molecules targeting PrP^Sc formation\n- Natural products with anti-prion activity\n\n**Immunotherapy Approaches:**\n- Active immunization with PrP antigens\n- Passive monoclonal antibody administration\n- Antibody fragments for better brain penetration\n- CAR-T cell approaches for prion clearance\n\n**Gene Therapy Strategies:**\n- PRNP knockdown using RNAi approaches\n- CRISPR-based gene editing for correction\n- PRNP expression modulation\n- Viral vector-mediated delivery of anti-prion constructs\n\n**Combination Therapies:**\n- Antibody plus small molecule combinations\n- Gene therapy with pharmacological adjuncts\n- Multi-target approaches for maximum effect\n\n### Protein Dynamics and Misfolding\n\n**Folding Pathways:**\n- PrP folding occurs in the endoplasmic reticulum\n- Misfolding can occur at multiple stages\n- Quality control mechanisms normally prevent accumulation\n- Failure of quality control leads to disease\n\n**Aggregation Mechanisms:**\n- Nucleation-dependent polymerization\n- Formation of oligomeric intermediates\n- Amyloid fibril assembly\n- Strain variation through different conformations\n\n**Cellular Quality Control:**\n- ER-associated degradation (ERAD)\n- Autophagy-lysosome pathway\n- Proteasome-mediated degradation\n- Unfolded protein response activation\n\n### PrP in Prion Disease Subtypes\n\n**Sporadic CJD (sCJD):**\n- Most common form (~85% of cases)\n- No known genetic or infectious cause\n- Likely spontaneous PrP^Sc formation\n- Variable clinical presentation based on PRNP genotype\n\n**Variant CJD (vCJD):**\n- Acquired from BSE exposure\n- Younger age of onset than sCJD\n- Prominent psychiatric features\n- Long incubation period\n\n**Iatrogenic CJD:**\n- Transmission through medical procedures\n- corneal transplants, dura mater grafts\n- Contaminated human growth hormone\n- Blood transfusion transmission documented\n\n**Fatal Familial Insomnia (FFI):**\n- PRNP D178N mutation with methionine at codon 129\n- Primary insomnia with autonomic dysfunction\n- Selective thalamic degeneration\n- Distinct clinical phenotype from CJD\n\n### PrP Structural Biology\n\n**X-ray Crystallography:**\n- Detailed structure of C-terminal domain\n- Insight into helix-turn-helix arrangement\n- Domain organization in the structured region\n\n**NMR Studies:**\n- Dynamics of N-terminal domain\n- Flexible regions in physiological conditions\n- Conformational changes upon misfolding\n\n**Cryo-EM:**\n- Amyloid fibril structures\n- Different prion strain conformations\n- Polymorphic fibril architectures\n\n### PrP in Neurodevelopment\n\n**Developmental Expression:**\n- High expression during embryogenesis\n- Peak levels in early postnatal period\n- Sustained expression in adult brain\n- Cell type-specific patterns\n\n**Developmental Functions:**\n- Neuronal differentiation\n- Synapse formation\n- Myelination\n- Astrocyte maturation\n\n**Knockout Phenotypes:**\n- Relatively mild phenotype in Prnp-/- mice\n- Compensatory mechanisms exist\n- Subtle neurological deficits in specific contexts\n\n### Research Methods\n\n**Biochemical Approaches:**\n- Western blotting for PrP detection\n- ELISA for quantification\n- Pulse-chase experiments for trafficking\n- Proteomics for interaction mapping\n\n**Cell Biology:**\n- Cell culture models (neurons, astrocytes)\n- Primary neuronal cultures\n- Stem cell-derived neurons\n- Live cell imaging\n\n**Animal Models:**\n- Mouse models of prion disease\n- Transgenic mice expressing mutant PRNP\n- Knock-in models with human PRNP\n- Zebrafish models for development\n\n**Structural Methods:**\n- X-ray crystallography\n- NMR spectroscopy\n- Cryo-electron microscopy\n- Mass spectrometry\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Prion Diseases](/diseases/prion-diseases)\n- [PRNP Gene](/genes/prnp)\n- [Amyloid-beta Protein](/proteins/amyloid-beta)\n- [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)\n- [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)\n\n---\n\n## External Links\n\n- **UniProt**: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)\n- **AlphaFold**: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)\n- **OMIM**: [176640 - PRNP](https://omim.org/entry/176640)\n- **GeneCards**: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)\n- **PubMed**: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)\n- **Human Protein Atlas**: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)\n- **STRING Database**: [PrP interaction network](https://string-db.org/)\n\n### Prion Disease Surveillance and Public Health\n\n**Global Surveillance Networks:**\n- National CJD surveillance systems\n- WHO collaborative surveillance\n- Rapid alert systems for new variants\n\n**BSE and Food Safety:**\n- Cattle testing protocols\n- Feed restrictions and controls\n- Human exposure risk assessment\n\n**Infection Control:**\n- Sterilization protocols for surgical equipment\n- Blood donor screening\n- Tissue transplantation safety\n\n### PrP and Copper Metabolism Connection\n\n**Copper Binding Properties:**\n- High affinity binding to octapeptide repeats\n- Different affinity for Cu(I) and Cu(II)\n- Multiple binding sites per PrP molecule\n\n**Copper Transport:**\n- PrP may function as copper receptor\n- Facilitates copper uptake into cells\n- Participates in cellular copper distribution\n\n**Implications for Disease:**\n- Copper dyshomeostasis in prion disease\n- Potential therapeutic targeting of copper pathways\n- Interaction with other neurodegenerative processes\n\n### PrP and Zinc Metabolism\n\n**Zinc Binding:**\n- PrP can bind zinc ions\n- Different binding site than copper\n- Modulates PrP aggregation properties\n\n**Zinc Signaling:**\n- Important for synaptic function\n- PrP may regulate zinc availability\n- Implications for synaptic plasticity\n\n### PrP in Oligodendrocyte Function\n\n**Myelin Maintenance:**\n- PrP expressed in oligodendrocytes\n- Important for myelin integrity\n- Dysfunction may contribute to demyelination\n\n**White Matter Pathology:**\n- White matter changes in CJD\n- Potential for therapeutic intervention\n- Imaging biomarkers for progression\n\n### PrP in Astrocyte Function\n\n**Astrocyte Expression:**\n- PrP expressed in astrocytes\n- Functions in astrocyte-neuron communication\n- May influence neurovascular unit\n\n**Reactive Astrocytosis:**\n- Astrocyte activation in prion disease\n- Both protective and harmful roles\n- Potential therapeutic target\n\n### PrP and Blood-Brain Barrier\n\n**BBB Regulation:**\n- PrP influences BBB development\n- Maintains BBB integrity\n- Dysfunction allows peripheral access\n\n**Therapeutic Implications:**\n- Drug delivery challenges\n- Strategies to improve brain penetration\n- Engineering of therapeutic antibodies\n\n### Genetic Epidemiology\n\n**Population Studies:**\n- Allele frequency variations\n- Founder mutations in specific populations\n- Consanguinity effects on incidence\n\n**Genotype-Phenotype Correlations:**\n- 129 polymorphism effects\n- Mutation-specific clinical presentations\n- Modifier genes and modifiers\n\n### PrP in Veterinary Medicine\n\n**Animal Prion Diseases:**\n- Scrapie in sheep and goats\n- BSE in cattle\n- Chronic wasting disease in cervids\n- Feline spongiform encephalopathy\n\n**Zoonotic Potential:**\n- Species barrier studies\n- Cross-species transmission\n- Public health implications\n\n### Future Research Directions\n\n**Basic Science Priorities:**\n- Structural basis for strain variation\n- Molecular mechanisms of neurotoxicity\n- Early diagnostic markers\n\n**Clinical Priorities:**\n- Disease-modifying therapies\n- Biomarkers for clinical trials\n- Early intervention strategies\n\n**Therapeutic Priorities:**\n- Small molecule development\n- Antibody therapeutics\n- Gene therapy approaches\n- Combination therapies\n\n---\n\n## References\n\n1. [Linden, Biology of the prion protein (2024)](https://doi.org/10.1016/j.sbi.2024.101527)\n2. [Watzlawik, Prion protein: structure and function (2023)](https://doi.org/10.1016/bs.pmbts.2023.02.001)\n3. [Caughey, Prion protein conversions (2023)](https://doi.org/10.1038/s41579-022-00771-4)\n4. [Aguib, Prion protein therapeutics (2022)](https://doi.org/10.1038/s41582-022-00635-8)\n5. [Prusiner, Prions (2015)](https://doi.org/10.1073/pnas.1514714112)\n6. [Caughey, Prion protein conversion in vitro (2014)](https://doi.org/10.1016/j.jmb.2014.02.009)\n7. [Soto, Prions: the biological particles that transmit neurodegenerative diseases (2011)](https://doi.org/10.4161/pri.5.3.16574)\n8. [Collins, Molecular genetics of human prion diseases (2001)]([DOI:10.1016/S0361-9230(01)00643-2](https://doi.org/10.1016/S0361-9230(01)00643-2))\n9. [Colby, Prions: propagation and evolution (2010)](https://doi.org/10.1007/82_2010_106)\n10. [Caughey, Prions and their potential therapeutic targeting (2009)](https://doi.org/10.2741/3376)\n11. [Soto, Challenges for prion disease diagnostics (2010)](https://doi.org/10.1007/s00018-010-0270-5)\n12. [Belay, Human prion diseases (1999)](https://doi.org/10.1128/CMR.12.2.281)\n13. [Johnson, Therapeutic approaches to prion disease (2005)](https://doi.org/10.1385/1-59259-848-3:331)\n14. [Caughey, Trends in prion biology and disease (2011)](https://doi.org/10.1042/ETLS20170039)\n15. [Geschwind, Prion diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25634165/)\n16. [Zanusso, Prion protein structural features and pathological isoforms (2016)](https://pubmed.ncbi.nlm.nih.gov/27689081/)\n17. [Purro, Prions and synaptic dysfunction (2012)](https://doi.org/10.4161/pri.20245)\n18. [Watts, Prion protein and Alzheimer disease: the end of the beginning? (2014)]([DOI:10.1016/S1474-4422(14)70158-1](https://doi.org/10.1016/S1474-4422(14)70158-1))\n19. [Bellinger, Prions in the brain and neurodegenerative disease (2015)](https://doi.org/10.1007/s11064-015-1577-2)\n20. [Soto, Functional role of the cellular prion protein in health and disease (2013)](https://doi.org/10.2217/fnl.13.42)\n21. [Hill et al., Prion disease diagnosis and RT-QuIC (2023)](https://pubmed.ncbi.nlm.nih.gov/37015345/)\n22. [Chen et al., Prion protein and metal ion homeostasis (2022)](https://doi.org/10.1016/j.ccr.2022.214891)\n23. [Biasini et al., Cellular prion protein and neuronal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)",
  "entity_type": "protein"
}

{
  "content_md": "# Prion Protein (PRNP)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Cellular Prion Protein (PrP)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[PRNP](/genes/prnp)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P04156\" target=\"_blank\">P04156</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>33-35 kDa (253 amino acids)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Family</td>\n    <td>Prion protein family</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Chromosome</td>\n    <td>20p13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Diseases</td>\n    <td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n# Cellular Prion Protein (PRNP)\n\n\n## Pathway / Mechanism Diagram\n\n```mermaid\nflowchart TD\n    A[\"Gene<br/>Expression\"] --> B[\"Prion  (PRNP)<br/>Protein\"]\n    B --> C[\"Protein<br/>Folding and Structure\"]\n    C --> D[\"Biological<br/>Activity\"]\n    D --> E[\"Cellular<br/>Function\"]\n    F[\"Regulation/<br/>Modification\"] --> D\n    E --> G[\"Normal<br/>Physiology\"]\n    B -->|\"mutation\"| H[\"Pathological<br/>State\"]\n    H --> I[\"Disease<br/>Phenotype\"]\n\n```\n\n## Introduction\n\nThe **cellular prion protein (PrP)**, encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].\n\nPrion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].\n\nBeyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].\n\n---\n\n## Structure and Biochemistry\n\n### Protein Architecture\n\nPrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:\n\n1. **N-terminal signal peptide (1-23 aa)**: Directs translocation to the endoplasmic reticulum\n2. **Flexible N-terminal domain (23-125 aa)**: Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)\n3. **Structured C-terminal domain (126-231 aa)**: Three α-helices and two β-strands forming a globular fold\n4. **GPI anchor signal (232-253 aa)**: Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment\n\n### Conformational States\n\nThe key property of PrP is its ability to adopt distinct conformational states:\n\n- **PrP^C (cellular)**: Predominantly α-helical, soluble, protease-sensitive, and non-infectious\n- **PrP^Sc (scrapie)**: Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation\n- **PrP^C** can be converted to **PrP^Sc** through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis\n\nThe structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].\n\n### Post-Translational Modifications\n\nPrP undergoes several important modifications:\n\n- **N-linked glycosylation** at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility\n- **Disulfide bond** between Cys179 and Cys214: Stabilizes the C-terminal globular domain\n- **GPI anchoring**: Targets PrP to lipid rafts in the plasma membrane\n- **Copper binding**: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity\n\n---\n\n## Normal Physiological Function\n\nDespite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:\n\n### Synaptic Function\n\nPrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:\n\n- Synaptic plasticity and long-term potentiation\n- Synaptic vesicle trafficking and neurotransmitter release\n- Maintenance of synaptic structure\n\n### Copper Homeostasis\n\nThe octapeptide repeat region binds copper ions with high affinity, suggesting a role in:\n\n- Cellular copper uptake and distribution\n- Antioxidant defense through copper-dependent enzymes\n- Modulation of synaptic copper signaling\n\n### Cell Signaling\n\nPrP interacts with multiple cell surface proteins and can:\n\n- Activate signaling cascades through various receptors\n- Interact with neural cell adhesion molecules\n- Modulate neuroprotective pathways\n\n### Neuroprotection\n\nPrP may provide neuroprotective effects through:\n\n- Anti-apoptotic signaling\n- Protection against oxidative stress\n- Regulation of autophagy\n\n---\n\n## Prion Diseases\n\n### Disease Spectrum\n\nPrion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:\n\n1. **Sporadic Creutzfeldt-Jakob Disease (sCJD)**: Most common form (~85% of cases), unknown etiology\n2. **Inherited Prion Diseases**: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion\n3. **Variant CJD (vCJD)**: Acquired from BSE-contaminated food products\n4. **Kuru**: Acquired through ritualistic cannibalism\n5. **Fatal Familial Insomnia (FFI)**: Characterized by progressive insomnia and autonomic dysfunction\n\n### Pathogenesis\n\nPrP^Sc accumulation in the brain leads to:\n\n- **Spongiform degeneration**: Vacuolation of brain tissue\n- **Neuronal loss**: Progressive death of neurons\n- **Gliosis**: Activation of astrocytes and microglia\n- **Amyloid plaque formation**: In some variants\n\nThe neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].\n\n### Genetic Susceptibility\n\nPolymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:\n\n- 129M/M: Predisposes to vCJD and certain CJD subtypes\n- 129V/V: Associated with longer incubation times\n- Heterozygosity may provide some protection\n\n---\n\n## Relationship to Alzheimer's Disease\n\nInteresting connections between PrP and AD have emerged [@Watts2014]:\n\n### PrP as an Aβ Receptor\n\nPrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:\n\n- Facilitate Aβ toxicity at synapses\n- Activate downstream signaling pathways\n- Contribute to early synaptic impairment in AD\n\n### Shared Mechanisms\n\nBoth prion diseases and AD involve:\n\n- Protein misfolding and aggregation\n- Synaptic loss\n- Progressive neurodegeneration\n- spreading through brain networks\n\n### Therapeutic Implications\n\nUnderstanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.\n\n### Molecular Mechanisms of PrP-Aβ Interaction\n\n**Binding Sites:**\n- The Aβ binding region on PrP is located in the N-terminal domain\n- Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding\n- The interaction is thought to be largely hydrophobic with some electrostatic components\n\n**Downstream Signaling:**\n- PrP-Aβ binding activates Fyn kinase\n- Leads to NMDA receptor phosphorylation\n- Results in excitotoxic calcium influx\n- Triggers downstream apoptotic pathways\n\n**Synaptic Effects:**\n- PrP mediates Aβ-induced synaptic spine loss\n- Impairs long-term potentiation (LTP)\n- Disrupts synaptic plasticity mechanisms\n- Contributes to early cognitive deficits\n\n### PrP in Other Neurodegenerative Diseases\n\n**Parkinson's Disease:**\n- PrP may interact with alpha-synuclein\n- Potential role in Lewy body formation\n- Possible influence on dopaminergic neuron survival\n\n**Huntington's Disease:**\n- PrP expression altered in HD models\n- May interact with mutant huntingtin\n- Potential contribution to synaptic dysfunction\n\n**Amyotrophic Lateral Sclerosis:**\n- PrP implicated in TDP-43 proteinopathy\n- Potential role in motor neuron vulnerability\n- May influence disease progression\n\n### PrP and Neuroinflammation\n\n**Microglial Activation:**\n- PrP can be released from neurons in exosomes\n- Extracellular PrP may activate microglia\n- Contributes to chronic neuroinflammation\n- Creates feedback loop promoting neurodegeneration\n\n**Cytokine Regulation:**\n- PrP influences cytokine production\n- Modulates inflammatory responses\n- May both promote and suppress inflammation depending on context\n\n**Blood-Brain Barrier:**\n- PrP affects BBB integrity\n- Dysregulation may allow peripheral immune cell entry\n- Contributes to neuroinflammatory processes\n\n### Cellular PrP Functions\n\n**Protein Quality Control:**\n- PrP interacts with cellular quality control machinery\n- May help target misfolded proteins for degradation\n- Loss of PrP function may impair protein clearance\n\n**Metal Ion Homeostasis:**\n- Copper binding is well-characterized\n- PrP may also bind other metal ions (zinc, iron)\n- Metal dyshomeostasis is implicated in multiple neurodegenerative diseases\n\n**Cell Adhesion:**\n- PrP functions as a cell adhesion molecule\n- Mediates cell-cell interactions at synapses\n- Influences neuronal connectivity during development\n\n### PrP in Aging and Cellular Senescence\n\n**Age-Related Changes:**\n- PrP expression changes with age\n- Oxidative modifications accumulate\n- May contribute to age-related neuronal vulnerability\n\n**Cellular Senescence:**\n- PrP may influence cellular senescence pathways\n- Senescent neurons show altered PrP expression\n- Could contribute to age-related neurodegeneration\n\n### PrP Spread and Propagation\n\n**Prion-Like Mechanisms:**\n- Aβ and tau can propagate via prion-like mechanisms\n- PrP may facilitate this spread\n- Template-driven misfolding in other proteins\n\n**Tissue-Specific Vulnerability:**\n- Neurons with high PrP expression are more vulnerable\n- Different brain regions show varying susceptibility\n- Regional PrP levels influence disease patterns\n\n### Biomarkers and Diagnostic Applications\n\n**Fluid Biomarkers:**\n- CSF PrP levels as potential biomarker\n- 14-3-3 protein in CSF for CJD diagnosis\n- Tau and neurofilament light chain measurements\n\n**Imaging Biomarkers:**\n- PET ligands for PrP aggregates\n- MRI for detecting spongiform changes\n- Diffusion tensor imaging for connectivity changes\n\n**Genetic Markers:**\n- PRNP polymorphisms modify disease risk\n- Codon 129 influences sporadic CJD\n- Octapeptide repeat number variations\n\n## Therapeutic Strategies\n\n### Current Approaches\n\nNo effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:\n\n1. **Anti-prion compounds**: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation\n2. **Immunotherapy**: Antibodies targeting PrP^Sc or preventing conversion\n3. **Gene silencing**: siRNA or antisense oligonucleotides to reduce PrP expression\n4. **Symptomatic treatment**: Managing cognitive and behavioral symptoms\n\n### Challenges\n\n- The blood-brain barrier limits drug delivery\n- PrP^Sc exists in multiple strains with distinct properties\n- Intervention must occur early in disease course\n- Need for reliable biomarkers to guide treatment\n- Heterogeneity of clinical presentations complicates diagnosis\n\n---\n\n## Specific Prion Disease Types\n\n### Sporadic Creutzfeldt-Jakob Disease (sCJD)\n\nsCJD represents approximately 85% of all human prion disease cases:\n\n**Epidemiology**\n- Incidence: 1-2 per million annually worldwide\n- Typically presents in individuals 50-70 years of age\n- Slight male predominance in some populations\n\n**Clinical Features**\n- Rapidly progressive dementia\n- Ataxia and cerebellar signs\n- Myoclonus (especially startle-induced)\n- Visual disturbances including cortical blindness\n- Pyramidal and extrapyramidal signs\n- Akinetic mutism in late stages\n\n**Subtypes**\n- MM1/MV1: Most common, rapid progression\n- VV2: Cerebellar predominant, slower progression\n- MM2: Longer disease duration\n\n**Diagnostic Features**\n- 14-3-3 protein in cerebrospinal fluid\n- Periodic sharp wave complexes on EEG\n- MRI hyperintensities in cortex and basal ganglia\n- Real-time quaking-induced conversion (RT-QuIC) positive\n\n### Variant Creutzfeldt-Jakob Disease (vCJD)\n\nvCJD results from exposure to bovine spongiform encephalopathy (BSE):\n\n**Epidemiology**\n- Linked to consumption of BSE-contaminated beef\n- First described in 1996 in the United Kingdom\n- Approximately 230 cases worldwide\n\n**Clinical Features**\n- Psychiatric symptoms at onset (depression, anxiety)\n- Behavioral changes and personality alterations\n- Sensory abnormalities including dysesthesia\n- Ataxia developing later in disease course\n- Progressive dementia\n- Longer survival than sCJD (median 14-18 months)\n\n**Pathological Features**\n- PrP amyloid plaques (florid plaques) throughout brain\n- PrP deposition in lymphoid tissues\n- Spongiform changes in basal ganglia and cerebellum\n\n### Fatal Familial Insomnia (FFI)\n\nFFI represents a unique prion disease with predominant sleep dysfunction:\n\n**Genetic Basis**\n- Caused by PRNP mutation D178N with methionine at codon 129\n- Autosomal dominant inheritance\n- Incomplete penetrance depending on codon 129 genotype\n\n**Clinical Features**\n- Progressive insomnia\n- Autonomic dysfunction (hyperhidrosis, hypertension)\n- Dysphagia and weight loss\n- Cognitive decline in later stages\n- Visual and auditory hallucinations\n\n**Neuropathology**\n- Selective thalamic degeneration, especially dorsomedial nucleus\n- Minimal spongiform change\n- PrP deposition in thalamus and inferior olive\n\n### Gerstmann-Sträussler-Scheinker Syndrome (GSS)\n\nGSS is a rare inherited prion disease:\n\n**Genetic Basis**\n- PRNP mutations including P102L, A117V, F198I, Q217R\n- Autosomal dominant inheritance\n- Variable age of onset (35-55 years typically)\n\n**Clinical Features**\n- Progressive ataxia\n- Dementia (later onset than ataxia)\n- Pyramidal signs\n- Extrapyramidal features in some subtypes\n- Disease duration: 2-10 years\n\n**Pathological Features**\n- PrP amyloid plaques throughout cerebellum and cerebral cortex\n- Multicentric plaque formation\n- Spongiform changes variable\n\n### Iatrogenic Prion Disease\n\nTransmission through medical procedures includes:\n\n**Sources of Transmission**\n- Dura mater grafts (historical)\n- Corneal transplants\n- Human growth hormone (historical)\n- Gonadotropin hormone\n- Blood transfusion (rare cases)\n\n**Clinical Features**\n- Similar to sCJD but longer incubation periods\n- For growth hormone cases: 5-20 year incubation\n- Typically rapid progression once symptomatic\n\n---\n\n## Cellular and Molecular Mechanisms\n\n### PrP^Sc Conversion Mechanism\n\nThe conversion of PrP^C to PrP^Sc involves:\n\n**Template-Directed Conversion**\n- PrP^Sc serves as template for conversion of PrP^C\n- Conformational information transfer through direct interaction\n- Heterodimer formation as intermediate\n\n**Nucleation-Dependent Polymerization**\n- PrP^Sc aggregates form through seeded polymerization\n- Lag phase followed by exponential growth\n- Fibril elongation through addition of monomers\n\n**Structural Transition**\n- Loss of α-helical content (from 40% to 20%)\n- Increase in β-sheet structure (from 10% to 40%)\n- Domain rearrangement in C-terminal region\n\n### PrP^Sc Strain Diversity\n\nPrion strains represent different conformations:\n\n**Strain Characteristics**\n- Distinct physicochemical properties\n- Different incubation periods in hosts\n- Variable neuropathology\n- Differential protease resistance patterns\n\n**Mechanisms of Strain Variation**\n- Different folding patterns of PrP^Sc\n- Variations in aggregation state\n- Distinct protofibril structures\n\n### Cellular Toxicity Pathways\n\nPrP^Sc causes neurotoxicity through multiple mechanisms:\n\n**ER Stress**\n- Accumulation of misfolded proteins triggers unfolded protein response\n- CHOP-mediated apoptosis\n- Disruption of calcium homeostasis\n\n**Oxidative Stress**\n- Mitochondrial dysfunction\n- Increased reactive oxygen species\n- Lipid peroxidation\n- DNA damage\n\n**Synaptic Dysfunction**\n- Loss of synaptic proteins\n- Impaired neurotransmitter release\n- Disruption of synaptic plasticity\n- Calcium dysregulation\n\n**Glial Activation**\n- Microglial activation and inflammation\n- Astrocyte reactivity\n- Cytokine release\n- Neuroinflammation amplification\n\n---\n\n## PrP and Other Neurodegenerative Diseases\n\n### PrP in Parkinson's Disease\n\nConnections between PrP and PD include:\n\n- PrP expression in dopaminergic neurons\n- Potential interaction with α-synuclein\n- Role in metal homeostasis relevant to PD\n- Possible common pathways in protein aggregation\n\n### PrP and Amyotrophic Lateral Sclerosis\n\nALS shares features with prion diseases:\n\n- PrP deposition in some ALS cases\n- Common mechanisms of protein aggregation\n- Overlapping pathways of cellular stress\n\n### Metal Ion Homeostasis\n\nPrP interacts with various metal ions:\n\n**Copper**\n- High affinity binding to octapeptide repeats\n- Role in copper uptake and distribution\n- Antioxidant function through SOD-like activity\n- Dyshomeostasis in prion disease\n\n**Iron**\n- PrP affects iron metabolism\n- Iron dysregulation in prion disease\n- Possible role in oxidative stress\n\n**Zinc**\n- PrP-zinc interactions\n- Potential signaling functions\n\n---\n\n## PrP as a Therapeutic Target\n\n### Immunotherapeutic Approaches\n\n**Active Immunization**\n- Vaccines targeting PrP^Sc\n- Generation of anti-PrP antibodies\n- Challenges: overcoming immune tolerance\n- Clinical trials in animal models\n\n**Passive Immunization**\n- Administration of anti-PrP monoclonal antibodies\n- Examples: 6D11, 8H4, Prioclone\n- Delivery challenges across blood-brain barrier\n\n### Small Molecule Inhibitors\n\n**Polyanionic Compounds**\n- Sulfated glycans inhibit PrP conversion\n- Pentosan polysulfate in clinical use\n- Limitations: poor BBB penetration\n\n**Tetracycline Derivatives**\n- Doxycycline shows anti-prion activity\n- Binding to PrP^Sc prevents aggregation\n- Clinical trials ongoing\n\n**Metal Chelators**\n- Cu/Zn chelation reduces conversion\n- Clioquinol trials in prion disease\n\n### Gene Silencing Approaches\n\n**Antisense Oligonucleotides**\n- Target PRNP mRNA\n- Reduce PrP^C expression\n- ASO trials in development\n- Advantages: specificity, distribution\n\n**RNAi Approaches**\n- siRNA targeting PRNP\n- Viral vector delivery\n- Challenges: efficient CNS delivery\n\n### Protein-Based Therapies\n\n**Dominant-Negative PrP**\n- Expression of mutant PrP that interferes with conversion\n- Competitive inhibition of PrP^Sc formation\n- Proof-of-concept in cell models\n\n**Chaperone-Based Approaches**\n- Heat shock proteins in PrP metabolism\n- Enhancement of PrP^C folding\n- Targeting protein quality control\n\n---\n\n## Diagnostic Biomarkers\n\n### Current Biomarkers\n\n**Cerebrospinal Fluid Markers**\n- 14-3-3 protein: sensitivity ~95%, specificity ~40%\n- Tau protein: elevated in some cases\n- Neurofilament light chain: promising marker\n\n**Real-Time Quaking-Induced Conversion (RT-QuIC)**\n- Sensitivity: 80-90% for sCJD\n- Specificity: >95%\n- Detects PrP^Sc seeding activity\n- Applied to CSF, olfactory epithelium, skin\n\n### Emerging Biomarkers\n\n**Blood-Based Markers**\n- PrP detection in plasma\n- Exosome-associated PrP^Sc\n- Sensitive detection methods in development\n\n**Imaging Biomarkers**\n- PET ligands for PrP^Sc\n- MRI advanced techniques\n- Diffusion tensor imaging\n\n---\n\n## Brain Atlas Resources\n\n- **Allen Human Brain Atlas**: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)\n- **Allen Mouse Brain Atlas**: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)\n- **BrainSpan Developmental Transcriptome**: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)\n\n### Clinical Trials and Emerging Therapies\n\n**Anti-Prion Compounds in Development:**\n- Polyanionic compounds that stabilize PrP^C\n- Small molecules targeting PrP^Sc formation\n- Natural products with anti-prion activity\n\n**Immunotherapy Approaches:**\n- Active immunization with PrP antigens\n- Passive monoclonal antibody administration\n- Antibody fragments for better brain penetration\n- CAR-T cell approaches for prion clearance\n\n**Gene Therapy Strategies:**\n- PRNP knockdown using RNAi approaches\n- CRISPR-based gene editing for correction\n- PRNP expression modulation\n- Viral vector-mediated delivery of anti-prion constructs\n\n**Combination Therapies:**\n- Antibody plus small molecule combinations\n- Gene therapy with pharmacological adjuncts\n- Multi-target approaches for maximum effect\n\n### Protein Dynamics and Misfolding\n\n**Folding Pathways:**\n- PrP folding occurs in the endoplasmic reticulum\n- Misfolding can occur at multiple stages\n- Quality control mechanisms normally prevent accumulation\n- Failure of quality control leads to disease\n\n**Aggregation Mechanisms:**\n- Nucleation-dependent polymerization\n- Formation of oligomeric intermediates\n- Amyloid fibril assembly\n- Strain variation through different conformations\n\n**Cellular Quality Control:**\n- ER-associated degradation (ERAD)\n- Autophagy-lysosome pathway\n- Proteasome-mediated degradation\n- Unfolded protein response activation\n\n### PrP in Prion Disease Subtypes\n\n**Sporadic CJD (sCJD):**\n- Most common form (~85% of cases)\n- No known genetic or infectious cause\n- Likely spontaneous PrP^Sc formation\n- Variable clinical presentation based on PRNP genotype\n\n**Variant CJD (vCJD):**\n- Acquired from BSE exposure\n- Younger age of onset than sCJD\n- Prominent psychiatric features\n- Long incubation period\n\n**Iatrogenic CJD:**\n- Transmission through medical procedures\n- corneal transplants, dura mater grafts\n- Contaminated human growth hormone\n- Blood transfusion transmission documented\n\n**Fatal Familial Insomnia (FFI):**\n- PRNP D178N mutation with methionine at codon 129\n- Primary insomnia with autonomic dysfunction\n- Selective thalamic degeneration\n- Distinct clinical phenotype from CJD\n\n### PrP Structural Biology\n\n**X-ray Crystallography:**\n- Detailed structure of C-terminal domain\n- Insight into helix-turn-helix arrangement\n- Domain organization in the structured region\n\n**NMR Studies:**\n- Dynamics of N-terminal domain\n- Flexible regions in physiological conditions\n- Conformational changes upon misfolding\n\n**Cryo-EM:**\n- Amyloid fibril structures\n- Different prion strain conformations\n- Polymorphic fibril architectures\n\n### PrP in Neurodevelopment\n\n**Developmental Expression:**\n- High expression during embryogenesis\n- Peak levels in early postnatal period\n- Sustained expression in adult brain\n- Cell type-specific patterns\n\n**Developmental Functions:**\n- Neuronal differentiation\n- Synapse formation\n- Myelination\n- Astrocyte maturation\n\n**Knockout Phenotypes:**\n- Relatively mild phenotype in Prnp-/- mice\n- Compensatory mechanisms exist\n- Subtle neurological deficits in specific contexts\n\n### Research Methods\n\n**Biochemical Approaches:**\n- Western blotting for PrP detection\n- ELISA for quantification\n- Pulse-chase experiments for trafficking\n- Proteomics for interaction mapping\n\n**Cell Biology:**\n- Cell culture models (neurons, astrocytes)\n- Primary neuronal cultures\n- Stem cell-derived neurons\n- Live cell imaging\n\n**Animal Models:**\n- Mouse models of prion disease\n- Transgenic mice expressing mutant PRNP\n- Knock-in models with human PRNP\n- Zebrafish models for development\n\n**Structural Methods:**\n- X-ray crystallography\n- NMR spectroscopy\n- Cryo-electron microscopy\n- Mass spectrometry\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Prion Diseases](/diseases/prion-diseases)\n- [PRNP Gene](/genes/prnp)\n- [Amyloid-beta Protein](/proteins/amyloid-beta)\n- [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)\n- [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)\n\n---\n\n## External Links\n\n- **UniProt**: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)\n- **AlphaFold**: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)\n- **OMIM**: [176640 - PRNP](https://omim.org/entry/176640)\n- **GeneCards**: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)\n- **PubMed**: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)\n- **Human Protein Atlas**: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)\n- **STRING Database**: [PrP interaction network](https://string-db.org/)\n\n### Prion Disease Surveillance and Public Health\n\n**Global Surveillance Networks:**\n- National CJD surveillance systems\n- WHO collaborative surveillance\n- Rapid alert systems for new variants\n\n**BSE and Food Safety:**\n- Cattle testing protocols\n- Feed restrictions and controls\n- Human exposure risk assessment\n\n**Infection Control:**\n- Sterilization protocols for surgical equipment\n- Blood donor screening\n- Tissue transplantation safety\n\n### PrP and Copper Metabolism Connection\n\n**Copper Binding Properties:**\n- High affinity binding to octapeptide repeats\n- Different affinity for Cu(I) and Cu(II)\n- Multiple binding sites per PrP molecule\n\n**Copper Transport:**\n- PrP may function as copper receptor\n- Facilitates copper uptake into cells\n- Participates in cellular copper distribution\n\n**Implications for Disease:**\n- Copper dyshomeostasis in prion disease\n- Potential therapeutic targeting of copper pathways\n- Interaction with other neurodegenerative processes\n\n### PrP and Zinc Metabolism\n\n**Zinc Binding:**\n- PrP can bind zinc ions\n- Different binding site than copper\n- Modulates PrP aggregation properties\n\n**Zinc Signaling:**\n- Important for synaptic function\n- PrP may regulate zinc availability\n- Implications for synaptic plasticity\n\n### PrP in Oligodendrocyte Function\n\n**Myelin Maintenance:**\n- PrP expressed in oligodendrocytes\n- Important for myelin integrity\n- Dysfunction may contribute to demyelination\n\n**White Matter Pathology:**\n- White matter changes in CJD\n- Potential for therapeutic intervention\n- Imaging biomarkers for progression\n\n### PrP in Astrocyte Function\n\n**Astrocyte Expression:**\n- PrP expressed in astrocytes\n- Functions in astrocyte-neuron communication\n- May influence neurovascular unit\n\n**Reactive Astrocytosis:**\n- Astrocyte activation in prion disease\n- Both protective and harmful roles\n- Potential therapeutic target\n\n### PrP and Blood-Brain Barrier\n\n**BBB Regulation:**\n- PrP influences BBB development\n- Maintains BBB integrity\n- Dysfunction allows peripheral access\n\n**Therapeutic Implications:**\n- Drug delivery challenges\n- Strategies to improve brain penetration\n- Engineering of therapeutic antibodies\n\n### Genetic Epidemiology\n\n**Population Studies:**\n- Allele frequency variations\n- Founder mutations in specific populations\n- Consanguinity effects on incidence\n\n**Genotype-Phenotype Correlations:**\n- 129 polymorphism effects\n- Mutation-specific clinical presentations\n- Modifier genes and modifiers\n\n### PrP in Veterinary Medicine\n\n**Animal Prion Diseases:**\n- Scrapie in sheep and goats\n- BSE in cattle\n- Chronic wasting disease in cervids\n- Feline spongiform encephalopathy\n\n**Zoonotic Potential:**\n- Species barrier studies\n- Cross-species transmission\n- Public health implications\n\n### Future Research Directions\n\n**Basic Science Priorities:**\n- Structural basis for strain variation\n- Molecular mechanisms of neurotoxicity\n- Early diagnostic markers\n\n**Clinical Priorities:**\n- Disease-modifying therapies\n- Biomarkers for clinical trials\n- Early intervention strategies\n\n**Therapeutic Priorities:**\n- Small molecule development\n- Antibody therapeutics\n- Gene therapy approaches\n- Combination therapies\n\n---\n\n## References\n\n1. [Linden, Biology of the prion protein (2024)](https://doi.org/10.1016/j.sbi.2024.101527)\n2. [Watzlawik, Prion protein: structure and function (2023)](https://doi.org/10.1016/bs.pmbts.2023.02.001)\n3. [Caughey, Prion protein conversions (2023)](https://doi.org/10.1038/s41579-022-00771-4)\n4. [Aguib, Prion protein therapeutics (2022)](https://doi.org/10.1038/s41582-022-00635-8)\n5. [Prusiner, Prions (2015)](https://doi.org/10.1073/pnas.1514714112)\n6. [Caughey, Prion protein conversion in vitro (2014)](https://doi.org/10.1016/j.jmb.2014.02.009)\n7. [Soto, Prions: the biological particles that transmit neurodegenerative diseases (2011)](https://doi.org/10.4161/pri.5.3.16574)\n8. [Collins, Molecular genetics of human prion diseases (2001)]([DOI:10.1016/S0361-9230(01)00643-2](https://doi.org/10.1016/S0361-9230(01)00643-2))\n9. [Colby, Prions: propagation and evolution (2010)](https://doi.org/10.1007/82_2010_106)\n10. [Caughey, Prions and their potential therapeutic targeting (2009)](https://doi.org/10.2741/3376)\n11. [Soto, Challenges for prion disease diagnostics (2010)](https://doi.org/10.1007/s00018-010-0270-5)\n12. [Belay, Human prion diseases (1999)](https://doi.org/10.1128/CMR.12.2.281)\n13. [Johnson, Therapeutic approaches to prion disease (2005)](https://doi.org/10.1385/1-59259-848-3:331)\n14. [Caughey, Trends in prion biology and disease (2011)](https://doi.org/10.1042/ETLS20170039)\n15. [Geschwind, Prion diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25634165/)\n16. [Zanusso, Prion protein structural features and pathological isoforms (2016)](https://pubmed.ncbi.nlm.nih.gov/27689081/)\n17. [Purro, Prions and synaptic dysfunction (2012)](https://doi.org/10.4161/pri.20245)\n18. [Watts, Prion protein and Alzheimer disease: the end of the beginning? (2014)]([DOI:10.1016/S1474-4422(14)70158-1](https://doi.org/10.1016/S1474-4422(14)70158-1))\n19. [Bellinger, Prions in the brain and neurodegenerative disease (2015)](https://doi.org/10.1007/s11064-015-1577-2)\n20. [Soto, Functional role of the cellular prion protein in health and disease (2013)](https://doi.org/10.2217/fnl.13.42)\n21. [Hill et al., Prion disease diagnosis and RT-QuIC (2023)](https://pubmed.ncbi.nlm.nih.gov/37015345/)\n22. [Chen et al., Prion protein and metal ion homeostasis (2022)](https://doi.org/10.1016/j.ccr.2022.214891)\n23. [Biasini et al., Cellular prion protein and neuronal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)",
  "entity_type": "protein"
}

{
  "content_md": "# Prion Protein (PRNP)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Cellular Prion Protein (PrP)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[PRNP](/genes/prnp)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P04156\" target=\"_blank\">P04156</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>33-35 kDa (253 amino acids)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Family</td>\n    <td>Prion protein family</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Chromosome</td>\n    <td>20p13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Diseases</td>\n    <td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n# Cellular Prion Protein (PRNP)\n\n\n## Pathway / Mechanism Diagram\n\n```mermaid\nflowchart TD\n    A[\"Gene<br/>Expression\"] --> B[\"Prion  (PRNP)<br/>Protein\"]\n    B --> C[\"Protein<br/>Folding & Structure\"]\n    C --> D[\"Biological<br/>Activity\"]\n    D --> E[\"Cellular<br/>Function\"]\n    F[\"Regulation/<br/>Modification\"] --> D\n    E --> G[\"Normal<br/>Physiology\"]\n    B -->|\"mutation\"| H[\"Pathological<br/>State\"]\n    H --> I[\"Disease<br/>Phenotype\"]\n```\n\n## Introduction\n\nThe **cellular prion protein (PrP)**, encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].\n\nPrion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].\n\nBeyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].\n\n---\n\n## Structure and Biochemistry\n\n### Protein Architecture\n\nPrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:\n\n1. **N-terminal signal peptide (1-23 aa)**: Directs translocation to the endoplasmic reticulum\n2. **Flexible N-terminal domain (23-125 aa)**: Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)\n3. **Structured C-terminal domain (126-231 aa)**: Three α-helices and two β-strands forming a globular fold\n4. **GPI anchor signal (232-253 aa)**: Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment\n\n### Conformational States\n\nThe key property of PrP is its ability to adopt distinct conformational states:\n\n- **PrP^C (cellular)**: Predominantly α-helical, soluble, protease-sensitive, and non-infectious\n- **PrP^Sc (scrapie)**: Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation\n- **PrP^C** can be converted to **PrP^Sc** through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis\n\nThe structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].\n\n### Post-Translational Modifications\n\nPrP undergoes several important modifications:\n\n- **N-linked glycosylation** at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility\n- **Disulfide bond** between Cys179 and Cys214: Stabilizes the C-terminal globular domain\n- **GPI anchoring**: Targets PrP to lipid rafts in the plasma membrane\n- **Copper binding**: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity\n\n---\n\n## Normal Physiological Function\n\nDespite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:\n\n### Synaptic Function\n\nPrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:\n\n- Synaptic plasticity and long-term potentiation\n- Synaptic vesicle trafficking and neurotransmitter release\n- Maintenance of synaptic structure\n\n### Copper Homeostasis\n\nThe octapeptide repeat region binds copper ions with high affinity, suggesting a role in:\n\n- Cellular copper uptake and distribution\n- Antioxidant defense through copper-dependent enzymes\n- Modulation of synaptic copper signaling\n\n### Cell Signaling\n\nPrP interacts with multiple cell surface proteins and can:\n\n- Activate signaling cascades through various receptors\n- Interact with neural cell adhesion molecules\n- Modulate neuroprotective pathways\n\n### Neuroprotection\n\nPrP may provide neuroprotective effects through:\n\n- Anti-apoptotic signaling\n- Protection against oxidative stress\n- Regulation of autophagy\n\n---\n\n## Prion Diseases\n\n### Disease Spectrum\n\nPrion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:\n\n1. **Sporadic Creutzfeldt-Jakob Disease (sCJD)**: Most common form (~85% of cases), unknown etiology\n2. **Inherited Prion Diseases**: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion\n3. **Variant CJD (vCJD)**: Acquired from BSE-contaminated food products\n4. **Kuru**: Acquired through ritualistic cannibalism\n5. **Fatal Familial Insomnia (FFI)**: Characterized by progressive insomnia and autonomic dysfunction\n\n### Pathogenesis\n\nPrP^Sc accumulation in the brain leads to:\n\n- **Spongiform degeneration**: Vacuolation of brain tissue\n- **Neuronal loss**: Progressive death of neurons\n- **Gliosis**: Activation of astrocytes and microglia\n- **Amyloid plaque formation**: In some variants\n\nThe neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].\n\n### Genetic Susceptibility\n\nPolymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:\n\n- 129M/M: Predisposes to vCJD and certain CJD subtypes\n- 129V/V: Associated with longer incubation times\n- Heterozygosity may provide some protection\n\n---\n\n## Relationship to Alzheimer's Disease\n\nInteresting connections between PrP and AD have emerged [@Watts2014]:\n\n### PrP as an Aβ Receptor\n\nPrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:\n\n- Facilitate Aβ toxicity at synapses\n- Activate downstream signaling pathways\n- Contribute to early synaptic impairment in AD\n\n### Shared Mechanisms\n\nBoth prion diseases and AD involve:\n\n- Protein misfolding and aggregation\n- Synaptic loss\n- Progressive neurodegeneration\n- spreading through brain networks\n\n### Therapeutic Implications\n\nUnderstanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.\n\n### Molecular Mechanisms of PrP-Aβ Interaction\n\n**Binding Sites:**\n- The Aβ binding region on PrP is located in the N-terminal domain\n- Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding\n- The interaction is thought to be largely hydrophobic with some electrostatic components\n\n**Downstream Signaling:**\n- PrP-Aβ binding activates Fyn kinase\n- Leads to NMDA receptor phosphorylation\n- Results in excitotoxic calcium influx\n- Triggers downstream apoptotic pathways\n\n**Synaptic Effects:**\n- PrP mediates Aβ-induced synaptic spine loss\n- Impairs long-term potentiation (LTP)\n- Disrupts synaptic plasticity mechanisms\n- Contributes to early cognitive deficits\n\n### PrP in Other Neurodegenerative Diseases\n\n**Parkinson's Disease:**\n- PrP may interact with alpha-synuclein\n- Potential role in Lewy body formation\n- Possible influence on dopaminergic neuron survival\n\n**Huntington's Disease:**\n- PrP expression altered in HD models\n- May interact with mutant huntingtin\n- Potential contribution to synaptic dysfunction\n\n**Amyotrophic Lateral Sclerosis:**\n- PrP implicated in TDP-43 proteinopathy\n- Potential role in motor neuron vulnerability\n- May influence disease progression\n\n### PrP and Neuroinflammation\n\n**Microglial Activation:**\n- PrP can be released from neurons in exosomes\n- Extracellular PrP may activate microglia\n- Contributes to chronic neuroinflammation\n- Creates feedback loop promoting neurodegeneration\n\n**Cytokine Regulation:**\n- PrP influences cytokine production\n- Modulates inflammatory responses\n- May both promote and suppress inflammation depending on context\n\n**Blood-Brain Barrier:**\n- PrP affects BBB integrity\n- Dysregulation may allow peripheral immune cell entry\n- Contributes to neuroinflammatory processes\n\n### Cellular PrP Functions\n\n**Protein Quality Control:**\n- PrP interacts with cellular quality control machinery\n- May help target misfolded proteins for degradation\n- Loss of PrP function may impair protein clearance\n\n**Metal Ion Homeostasis:**\n- Copper binding is well-characterized\n- PrP may also bind other metal ions (zinc, iron)\n- Metal dyshomeostasis is implicated in multiple neurodegenerative diseases\n\n**Cell Adhesion:**\n- PrP functions as a cell adhesion molecule\n- Mediates cell-cell interactions at synapses\n- Influences neuronal connectivity during development\n\n### PrP in Aging and Cellular Senescence\n\n**Age-Related Changes:**\n- PrP expression changes with age\n- Oxidative modifications accumulate\n- May contribute to age-related neuronal vulnerability\n\n**Cellular Senescence:**\n- PrP may influence cellular senescence pathways\n- Senescent neurons show altered PrP expression\n- Could contribute to age-related neurodegeneration\n\n### PrP Spread and Propagation\n\n**Prion-Like Mechanisms:**\n- Aβ and tau can propagate via prion-like mechanisms\n- PrP may facilitate this spread\n- Template-driven misfolding in other proteins\n\n**Tissue-Specific Vulnerability:**\n- Neurons with high PrP expression are more vulnerable\n- Different brain regions show varying susceptibility\n- Regional PrP levels influence disease patterns\n\n### Biomarkers and Diagnostic Applications\n\n**Fluid Biomarkers:**\n- CSF PrP levels as potential biomarker\n- 14-3-3 protein in CSF for CJD diagnosis\n- Tau and neurofilament light chain measurements\n\n**Imaging Biomarkers:**\n- PET ligands for PrP aggregates\n- MRI for detecting spongiform changes\n- Diffusion tensor imaging for connectivity changes\n\n**Genetic Markers:**\n- PRNP polymorphisms modify disease risk\n- Codon 129 influences sporadic CJD\n- Octapeptide repeat number variations\n\n## Therapeutic Strategies\n\n### Current Approaches\n\nNo effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:\n\n1. **Anti-prion compounds**: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation\n2. **Immunotherapy**: Antibodies targeting PrP^Sc or preventing conversion\n3. **Gene silencing**: siRNA or antisense oligonucleotides to reduce PrP expression\n4. **Symptomatic treatment**: Managing cognitive and behavioral symptoms\n\n### Challenges\n\n- The blood-brain barrier limits drug delivery\n- PrP^Sc exists in multiple strains with distinct properties\n- Intervention must occur early in disease course\n- Need for reliable biomarkers to guide treatment\n- Heterogeneity of clinical presentations complicates diagnosis\n\n---\n\n## Specific Prion Disease Types\n\n### Sporadic Creutzfeldt-Jakob Disease (sCJD)\n\nsCJD represents approximately 85% of all human prion disease cases:\n\n**Epidemiology**\n- Incidence: 1-2 per million annually worldwide\n- Typically presents in individuals 50-70 years of age\n- Slight male predominance in some populations\n\n**Clinical Features**\n- Rapidly progressive dementia\n- Ataxia and cerebellar signs\n- Myoclonus (especially startle-induced)\n- Visual disturbances including cortical blindness\n- Pyramidal and extrapyramidal signs\n- Akinetic mutism in late stages\n\n**Subtypes**\n- MM1/MV1: Most common, rapid progression\n- VV2: Cerebellar predominant, slower progression\n- MM2: Longer disease duration\n\n**Diagnostic Features**\n- 14-3-3 protein in cerebrospinal fluid\n- Periodic sharp wave complexes on EEG\n- MRI hyperintensities in cortex and basal ganglia\n- Real-time quaking-induced conversion (RT-QuIC) positive\n\n### Variant Creutzfeldt-Jakob Disease (vCJD)\n\nvCJD results from exposure to bovine spongiform encephalopathy (BSE):\n\n**Epidemiology**\n- Linked to consumption of BSE-contaminated beef\n- First described in 1996 in the United Kingdom\n- Approximately 230 cases worldwide\n\n**Clinical Features**\n- Psychiatric symptoms at onset (depression, anxiety)\n- Behavioral changes and personality alterations\n- Sensory abnormalities including dysesthesia\n- Ataxia developing later in disease course\n- Progressive dementia\n- Longer survival than sCJD (median 14-18 months)\n\n**Pathological Features**\n- PrP amyloid plaques (florid plaques) throughout brain\n- PrP deposition in lymphoid tissues\n- Spongiform changes in basal ganglia and cerebellum\n\n### Fatal Familial Insomnia (FFI)\n\nFFI represents a unique prion disease with predominant sleep dysfunction:\n\n**Genetic Basis**\n- Caused by PRNP mutation D178N with methionine at codon 129\n- Autosomal dominant inheritance\n- Incomplete penetrance depending on codon 129 genotype\n\n**Clinical Features**\n- Progressive insomnia\n- Autonomic dysfunction (hyperhidrosis, hypertension)\n- Dysphagia and weight loss\n- Cognitive decline in later stages\n- Visual and auditory hallucinations\n\n**Neuropathology**\n- Selective thalamic degeneration, especially dorsomedial nucleus\n- Minimal spongiform change\n- PrP deposition in thalamus and inferior olive\n\n### Gerstmann-Sträussler-Scheinker Syndrome (GSS)\n\nGSS is a rare inherited prion disease:\n\n**Genetic Basis**\n- PRNP mutations including P102L, A117V, F198I, Q217R\n- Autosomal dominant inheritance\n- Variable age of onset (35-55 years typically)\n\n**Clinical Features**\n- Progressive ataxia\n- Dementia (later onset than ataxia)\n- Pyramidal signs\n- Extrapyramidal features in some subtypes\n- Disease duration: 2-10 years\n\n**Pathological Features**\n- PrP amyloid plaques throughout cerebellum and cerebral cortex\n- Multicentric plaque formation\n- Spongiform changes variable\n\n### Iatrogenic Prion Disease\n\nTransmission through medical procedures includes:\n\n**Sources of Transmission**\n- Dura mater grafts (historical)\n- Corneal transplants\n- Human growth hormone (historical)\n- Gonadotropin hormone\n- Blood transfusion (rare cases)\n\n**Clinical Features**\n- Similar to sCJD but longer incubation periods\n- For growth hormone cases: 5-20 year incubation\n- Typically rapid progression once symptomatic\n\n---\n\n## Cellular and Molecular Mechanisms\n\n### PrP^Sc Conversion Mechanism\n\nThe conversion of PrP^C to PrP^Sc involves:\n\n**Template-Directed Conversion**\n- PrP^Sc serves as template for conversion of PrP^C\n- Conformational information transfer through direct interaction\n- Heterodimer formation as intermediate\n\n**Nucleation-Dependent Polymerization**\n- PrP^Sc aggregates form through seeded polymerization\n- Lag phase followed by exponential growth\n- Fibril elongation through addition of monomers\n\n**Structural Transition**\n- Loss of α-helical content (from 40% to 20%)\n- Increase in β-sheet structure (from 10% to 40%)\n- Domain rearrangement in C-terminal region\n\n### PrP^Sc Strain Diversity\n\nPrion strains represent different conformations:\n\n**Strain Characteristics**\n- Distinct physicochemical properties\n- Different incubation periods in hosts\n- Variable neuropathology\n- Differential protease resistance patterns\n\n**Mechanisms of Strain Variation**\n- Different folding patterns of PrP^Sc\n- Variations in aggregation state\n- Distinct protofibril structures\n\n### Cellular Toxicity Pathways\n\nPrP^Sc causes neurotoxicity through multiple mechanisms:\n\n**ER Stress**\n- Accumulation of misfolded proteins triggers unfolded protein response\n- CHOP-mediated apoptosis\n- Disruption of calcium homeostasis\n\n**Oxidative Stress**\n- Mitochondrial dysfunction\n- Increased reactive oxygen species\n- Lipid peroxidation\n- DNA damage\n\n**Synaptic Dysfunction**\n- Loss of synaptic proteins\n- Impaired neurotransmitter release\n- Disruption of synaptic plasticity\n- Calcium dysregulation\n\n**Glial Activation**\n- Microglial activation and inflammation\n- Astrocyte reactivity\n- Cytokine release\n- Neuroinflammation amplification\n\n---\n\n## PrP and Other Neurodegenerative Diseases\n\n### PrP in Parkinson's Disease\n\nConnections between PrP and PD include:\n\n- PrP expression in dopaminergic neurons\n- Potential interaction with α-synuclein\n- Role in metal homeostasis relevant to PD\n- Possible common pathways in protein aggregation\n\n### PrP and Amyotrophic Lateral Sclerosis\n\nALS shares features with prion diseases:\n\n- PrP deposition in some ALS cases\n- Common mechanisms of protein aggregation\n- Overlapping pathways of cellular stress\n\n### Metal Ion Homeostasis\n\nPrP interacts with various metal ions:\n\n**Copper**\n- High affinity binding to octapeptide repeats\n- Role in copper uptake and distribution\n- Antioxidant function through SOD-like activity\n- Dyshomeostasis in prion disease\n\n**Iron**\n- PrP affects iron metabolism\n- Iron dysregulation in prion disease\n- Possible role in oxidative stress\n\n**Zinc**\n- PrP-zinc interactions\n- Potential signaling functions\n\n---\n\n## PrP as a Therapeutic Target\n\n### Immunotherapeutic Approaches\n\n**Active Immunization**\n- Vaccines targeting PrP^Sc\n- Generation of anti-PrP antibodies\n- Challenges: overcoming immune tolerance\n- Clinical trials in animal models\n\n**Passive Immunization**\n- Administration of anti-PrP monoclonal antibodies\n- Examples: 6D11, 8H4, Prioclone\n- Delivery challenges across blood-brain barrier\n\n### Small Molecule Inhibitors\n\n**Polyanionic Compounds**\n- Sulfated glycans inhibit PrP conversion\n- Pentosan polysulfate in clinical use\n- Limitations: poor BBB penetration\n\n**Tetracycline Derivatives**\n- Doxycycline shows anti-prion activity\n- Binding to PrP^Sc prevents aggregation\n- Clinical trials ongoing\n\n**Metal Chelators**\n- Cu/Zn chelation reduces conversion\n- Clioquinol trials in prion disease\n\n### Gene Silencing Approaches\n\n**Antisense Oligonucleotides**\n- Target PRNP mRNA\n- Reduce PrP^C expression\n- ASO trials in development\n- Advantages: specificity, distribution\n\n**RNAi Approaches**\n- siRNA targeting PRNP\n- Viral vector delivery\n- Challenges: efficient CNS delivery\n\n### Protein-Based Therapies\n\n**Dominant-Negative PrP**\n- Expression of mutant PrP that interferes with conversion\n- Competitive inhibition of PrP^Sc formation\n- Proof-of-concept in cell models\n\n**Chaperone-Based Approaches**\n- Heat shock proteins in PrP metabolism\n- Enhancement of PrP^C folding\n- Targeting protein quality control\n\n---\n\n## Diagnostic Biomarkers\n\n### Current Biomarkers\n\n**Cerebrospinal Fluid Markers**\n- 14-3-3 protein: sensitivity ~95%, specificity ~40%\n- Tau protein: elevated in some cases\n- Neurofilament light chain: promising marker\n\n**Real-Time Quaking-Induced Conversion (RT-QuIC)**\n- Sensitivity: 80-90% for sCJD\n- Specificity: >95%\n- Detects PrP^Sc seeding activity\n- Applied to CSF, olfactory epithelium, skin\n\n### Emerging Biomarkers\n\n**Blood-Based Markers**\n- PrP detection in plasma\n- Exosome-associated PrP^Sc\n- Sensitive detection methods in development\n\n**Imaging Biomarkers**\n- PET ligands for PrP^Sc\n- MRI advanced techniques\n- Diffusion tensor imaging\n\n---\n\n## Brain Atlas Resources\n\n- **Allen Human Brain Atlas**: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)\n- **Allen Mouse Brain Atlas**: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)\n- **BrainSpan Developmental Transcriptome**: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)\n\n### Clinical Trials and Emerging Therapies\n\n**Anti-Prion Compounds in Development:**\n- Polyanionic compounds that stabilize PrP^C\n- Small molecules targeting PrP^Sc formation\n- Natural products with anti-prion activity\n\n**Immunotherapy Approaches:**\n- Active immunization with PrP antigens\n- Passive monoclonal antibody administration\n- Antibody fragments for better brain penetration\n- CAR-T cell approaches for prion clearance\n\n**Gene Therapy Strategies:**\n- PRNP knockdown using RNAi approaches\n- CRISPR-based gene editing for correction\n- PRNP expression modulation\n- Viral vector-mediated delivery of anti-prion constructs\n\n**Combination Therapies:**\n- Antibody plus small molecule combinations\n- Gene therapy with pharmacological adjuncts\n- Multi-target approaches for maximum effect\n\n### Protein Dynamics and Misfolding\n\n**Folding Pathways:**\n- PrP folding occurs in the endoplasmic reticulum\n- Misfolding can occur at multiple stages\n- Quality control mechanisms normally prevent accumulation\n- Failure of quality control leads to disease\n\n**Aggregation Mechanisms:**\n- Nucleation-dependent polymerization\n- Formation of oligomeric intermediates\n- Amyloid fibril assembly\n- Strain variation through different conformations\n\n**Cellular Quality Control:**\n- ER-associated degradation (ERAD)\n- Autophagy-lysosome pathway\n- Proteasome-mediated degradation\n- Unfolded protein response activation\n\n### PrP in Prion Disease Subtypes\n\n**Sporadic CJD (sCJD):**\n- Most common form (~85% of cases)\n- No known genetic or infectious cause\n- Likely spontaneous PrP^Sc formation\n- Variable clinical presentation based on PRNP genotype\n\n**Variant CJD (vCJD):**\n- Acquired from BSE exposure\n- Younger age of onset than sCJD\n- Prominent psychiatric features\n- Long incubation period\n\n**Iatrogenic CJD:**\n- Transmission through medical procedures\n- corneal transplants, dura mater grafts\n- Contaminated human growth hormone\n- Blood transfusion transmission documented\n\n**Fatal Familial Insomnia (FFI):**\n- PRNP D178N mutation with methionine at codon 129\n- Primary insomnia with autonomic dysfunction\n- Selective thalamic degeneration\n- Distinct clinical phenotype from CJD\n\n### PrP Structural Biology\n\n**X-ray Crystallography:**\n- Detailed structure of C-terminal domain\n- Insight into helix-turn-helix arrangement\n- Domain organization in the structured region\n\n**NMR Studies:**\n- Dynamics of N-terminal domain\n- Flexible regions in physiological conditions\n- Conformational changes upon misfolding\n\n**Cryo-EM:**\n- Amyloid fibril structures\n- Different prion strain conformations\n- Polymorphic fibril architectures\n\n### PrP in Neurodevelopment\n\n**Developmental Expression:**\n- High expression during embryogenesis\n- Peak levels in early postnatal period\n- Sustained expression in adult brain\n- Cell type-specific patterns\n\n**Developmental Functions:**\n- Neuronal differentiation\n- Synapse formation\n- Myelination\n- Astrocyte maturation\n\n**Knockout Phenotypes:**\n- Relatively mild phenotype in Prnp-/- mice\n- Compensatory mechanisms exist\n- Subtle neurological deficits in specific contexts\n\n### Research Methods\n\n**Biochemical Approaches:**\n- Western blotting for PrP detection\n- ELISA for quantification\n- Pulse-chase experiments for trafficking\n- Proteomics for interaction mapping\n\n**Cell Biology:**\n- Cell culture models (neurons, astrocytes)\n- Primary neuronal cultures\n- Stem cell-derived neurons\n- Live cell imaging\n\n**Animal Models:**\n- Mouse models of prion disease\n- Transgenic mice expressing mutant PRNP\n- Knock-in models with human PRNP\n- Zebrafish models for development\n\n**Structural Methods:**\n- X-ray crystallography\n- NMR spectroscopy\n- Cryo-electron microscopy\n- Mass spectrometry\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Prion Diseases](/diseases/prion-diseases)\n- [PRNP Gene](/genes/prnp)\n- [Amyloid-beta Protein](/proteins/amyloid-beta)\n- [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)\n- [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)\n\n---\n\n## External Links\n\n- **UniProt**: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)\n- **AlphaFold**: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)\n- **OMIM**: [176640 - PRNP](https://omim.org/entry/176640)\n- **GeneCards**: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)\n- **PubMed**: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)\n- **Human Protein Atlas**: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)\n- **STRING Database**: [PrP interaction network](https://string-db.org/)\n\n### Prion Disease Surveillance and Public Health\n\n**Global Surveillance Networks:**\n- National CJD surveillance systems\n- WHO collaborative surveillance\n- Rapid alert systems for new variants\n\n**BSE and Food Safety:**\n- Cattle testing protocols\n- Feed restrictions and controls\n- Human exposure risk assessment\n\n**Infection Control:**\n- Sterilization protocols for surgical equipment\n- Blood donor screening\n- Tissue transplantation safety\n\n### PrP and Copper Metabolism Connection\n\n**Copper Binding Properties:**\n- High affinity binding to octapeptide repeats\n- Different affinity for Cu(I) and Cu(II)\n- Multiple binding sites per PrP molecule\n\n**Copper Transport:**\n- PrP may function as copper receptor\n- Facilitates copper uptake into cells\n- Participates in cellular copper distribution\n\n**Implications for Disease:**\n- Copper dyshomeostasis in prion disease\n- Potential therapeutic targeting of copper pathways\n- Interaction with other neurodegenerative processes\n\n### PrP and Zinc Metabolism\n\n**Zinc Binding:**\n- PrP can bind zinc ions\n- Different binding site than copper\n- Modulates PrP aggregation properties\n\n**Zinc Signaling:**\n- Important for synaptic function\n- PrP may regulate zinc availability\n- Implications for synaptic plasticity\n\n### PrP in Oligodendrocyte Function\n\n**Myelin Maintenance:**\n- PrP expressed in oligodendrocytes\n- Important for myelin integrity\n- Dysfunction may contribute to demyelination\n\n**White Matter Pathology:**\n- White matter changes in CJD\n- Potential for therapeutic intervention\n- Imaging biomarkers for progression\n\n### PrP in Astrocyte Function\n\n**Astrocyte Expression:**\n- PrP expressed in astrocytes\n- Functions in astrocyte-neuron communication\n- May influence neurovascular unit\n\n**Reactive Astrocytosis:**\n- Astrocyte activation in prion disease\n- Both protective and harmful roles\n- Potential therapeutic target\n\n### PrP and Blood-Brain Barrier\n\n**BBB Regulation:**\n- PrP influences BBB development\n- Maintains BBB integrity\n- Dysfunction allows peripheral access\n\n**Therapeutic Implications:**\n- Drug delivery challenges\n- Strategies to improve brain penetration\n- Engineering of therapeutic antibodies\n\n### Genetic Epidemiology\n\n**Population Studies:**\n- Allele frequency variations\n- Founder mutations in specific populations\n- Consanguinity effects on incidence\n\n**Genotype-Phenotype Correlations:**\n- 129 polymorphism effects\n- Mutation-specific clinical presentations\n- Modifier genes and modifiers\n\n### PrP in Veterinary Medicine\n\n**Animal Prion Diseases:**\n- Scrapie in sheep and goats\n- BSE in cattle\n- Chronic wasting disease in cervids\n- Feline spongiform encephalopathy\n\n**Zoonotic Potential:**\n- Species barrier studies\n- Cross-species transmission\n- Public health implications\n\n### Future Research Directions\n\n**Basic Science Priorities:**\n- Structural basis for strain variation\n- Molecular mechanisms of neurotoxicity\n- Early diagnostic markers\n\n**Clinical Priorities:**\n- Disease-modifying therapies\n- Biomarkers for clinical trials\n- Early intervention strategies\n\n**Therapeutic Priorities:**\n- Small molecule development\n- Antibody therapeutics\n- Gene therapy approaches\n- Combination therapies\n\n---\n\n## References\n\n1. [Linden, Biology of the prion protein (2024)](https://doi.org/10.1016/j.sbi.2024.101527)\n2. [Watzlawik, Prion protein: structure and function (2023)](https://doi.org/10.1016/bs.pmbts.2023.02.001)\n3. [Caughey, Prion protein conversions (2023)](https://doi.org/10.1038/s41579-022-00771-4)\n4. [Aguib, Prion protein therapeutics (2022)](https://doi.org/10.1038/s41582-022-00635-8)\n5. [Prusiner, Prions (2015)](https://doi.org/10.1073/pnas.1514714112)\n6. [Caughey, Prion protein conversion in vitro (2014)](https://doi.org/10.1016/j.jmb.2014.02.009)\n7. [Soto, Prions: the biological particles that transmit neurodegenerative diseases (2011)](https://doi.org/10.4161/pri.5.3.16574)\n8. [Collins, Molecular genetics of human prion diseases (2001)]([DOI:10.1016/S0361-9230(01)00643-2](https://doi.org/10.1016/S0361-9230(01)00643-2))\n9. [Colby, Prions: propagation and evolution (2010)](https://doi.org/10.1007/82_2010_106)\n10. [Caughey, Prions and their potential therapeutic targeting (2009)](https://doi.org/10.2741/3376)\n11. [Soto, Challenges for prion disease diagnostics (2010)](https://doi.org/10.1007/s00018-010-0270-5)\n12. [Belay, Human prion diseases (1999)](https://doi.org/10.1128/CMR.12.2.281)\n13. [Johnson, Therapeutic approaches to prion disease (2005)](https://doi.org/10.1385/1-59259-848-3:331)\n14. [Caughey, Trends in prion biology and disease (2011)](https://doi.org/10.1042/ETLS20170039)\n15. [Geschwind, Prion diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25634165/)\n16. [Zanusso, Prion protein structural features and pathological isoforms (2016)](https://pubmed.ncbi.nlm.nih.gov/27689081/)\n17. [Purro, Prions and synaptic dysfunction (2012)](https://doi.org/10.4161/pri.20245)\n18. [Watts, Prion protein and Alzheimer disease: the end of the beginning? (2014)]([DOI:10.1016/S1474-4422(14)70158-1](https://doi.org/10.1016/S1474-4422(14)70158-1))\n19. [Bellinger, Prions in the brain and neurodegenerative disease (2015)](https://doi.org/10.1007/s11064-015-1577-2)\n20. [Soto, Functional role of the cellular prion protein in health and disease (2013)](https://doi.org/10.2217/fnl.13.42)\n21. [Hill et al., Prion disease diagnosis and RT-QuIC (2023)](https://pubmed.ncbi.nlm.nih.gov/37015345/)\n22. [Chen et al., Prion protein and metal ion homeostasis (2022)](https://doi.org/10.1016/j.ccr.2022.214891)\n23. [Biasini et al., Cellular prion protein and neuronal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)",
  "entity_type": "protein"
}

{
  "content_md": "<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Cellular Prion Protein (PrP)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[PRNP](/genes/prnp)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P04156\" target=\"_blank\">P04156</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>33-35 kDa (253 amino acids)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Cell membrane ( GPI-anchored), cytoplasm, nucleus</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Family</td>\n    <td>Prion protein family</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Chromosome</td>\n    <td>20p13</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Diseases</td>\n    <td>[Creutzfeldt-Jakob Disease](/diseases/prion-diseases), Fatal Familial Insomnia, Kuru, Bovine Spongiform Encephalopathy</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n# Cellular Prion Protein (PRNP)\n\n\n## Pathway / Mechanism Diagram\n\n```mermaid\nflowchart TD\n    A[\"Gene<br/>Expression\"] --> B[\"Prion  (PRNP)<br/>Protein\"]\n    B --> C[\"Protein<br/>Folding & Structure\"]\n    C --> D[\"Biological<br/>Activity\"]\n    D --> E[\"Cellular<br/>Function\"]\n    F[\"Regulation/<br/>Modification\"] --> D\n    E --> G[\"Normal<br/>Physiology\"]\n    B -->|\"mutation\"| H[\"Pathological<br/>State\"]\n    H --> I[\"Disease<br/>Phenotype\"]\n```\n\n## Introduction\n\nThe **cellular prion protein (PrP)**, encoded by the [PRNP](/genes/prnp) gene, is a GPI-anchored glycoprotein expressed predominantly in the central nervous system. While its precise physiological function remains incompletely understood, PrP is best known for its central role in prion diseases—a unique class of fatal neurodegenerative disorders caused by the pathological conversion of the normal cellular isoform (PrP^C) into an infectious, self-propagating isoform (PrP^Sc) [@Linden2024][@Watzlawik2023].\n\nPrion diseases include [Creutzfeldt-Jakob disease](/diseases/prion-diseases) (CJD), fatal familial insomnia (FFI), kuru, and variant CJD linked to bovine spongiform encephalopathy (BSE). These disorders represent a paradigm in neurodegeneration where a single protein can undergo a conformational transformation that triggers progressive neurotoxicity and spongiform changes in the brain. The discovery that prion diseases can be infectious, inherited, and sporadic has fundamentally transformed our understanding of protein misfolding in neurodegeneration [@Prusiner2015][@Caughey2023].\n\nBeyond its role in prion diseases, PrP has been implicated in other neurodegenerative conditions, including [Alzheimer's disease](/diseases/alzheimers-disease), where interactions between PrP and amyloid-beta may influence disease pathogenesis [@Watts2014].\n\n---\n\n## Structure and Biochemistry\n\n### Protein Architecture\n\nPrP is a 253-amino acid protein with a distinctive domain structure [@Watzlawik2023][@Zanusso2016]:\n\n1. **N-terminal signal peptide (1-23 aa)**: Directs translocation to the endoplasmic reticulum\n2. **Flexible N-terminal domain (23-125 aa)**: Contains five octapeptide repeats that coordinate copper ions (Cu²⁺)\n3. **Structured C-terminal domain (126-231 aa)**: Three α-helices and two β-strands forming a globular fold\n4. **GPI anchor signal (232-253 aa)**: Directs addition of the glycosylphosphatidylinositol anchor for membrane attachment\n\n### Conformational States\n\nThe key property of PrP is its ability to adopt distinct conformational states:\n\n- **PrP^C (cellular)**: Predominantly α-helical, soluble, protease-sensitive, and non-infectious\n- **PrP^Sc (scrapie)**: Enriched in β-sheet structure, insoluble, partially protease-resistant, and capable of self-propagation\n- **PrP^C** can be converted to **PrP^Sc** through interaction with existing PrP^Sc seeds, a process central to prion disease pathogenesis\n\nThe structural transition from α-helix to β-sheet is the molecular basis of prion propagation and the formation of amyloid fibrils that accumulate in the brain [@Caughey2014][@Soto2011].\n\n### Post-Translational Modifications\n\nPrP undergoes several important modifications:\n\n- **N-linked glycosylation** at Asn181 and Asn197: Affects folding, trafficking, and disease susceptibility\n- **Disulfide bond** between Cys179 and Cys214: Stabilizes the C-terminal globular domain\n- **GPI anchoring**: Targets PrP to lipid rafts in the plasma membrane\n- **Copper binding**: The octapeptide repeats can coordinate Cu²⁺ ions with varying affinity\n\n---\n\n## Normal Physiological Function\n\nDespite extensive research, the physiological functions of PrP remain incompletely defined. Several lines of evidence support important roles in:\n\n### Synaptic Function\n\nPrP is highly expressed at synapses, particularly in the [hippocampus](/brain-regions/hippocampus) and [cerebellum](/brain-regions/cerebellum). Studies suggest it participates in [@Purro2012][@Bellinger2015]:\n\n- Synaptic plasticity and long-term potentiation\n- Synaptic vesicle trafficking and neurotransmitter release\n- Maintenance of synaptic structure\n\n### Copper Homeostasis\n\nThe octapeptide repeat region binds copper ions with high affinity, suggesting a role in:\n\n- Cellular copper uptake and distribution\n- Antioxidant defense through copper-dependent enzymes\n- Modulation of synaptic copper signaling\n\n### Cell Signaling\n\nPrP interacts with multiple cell surface proteins and can:\n\n- Activate signaling cascades through various receptors\n- Interact with neural cell adhesion molecules\n- Modulate neuroprotective pathways\n\n### Neuroprotection\n\nPrP may provide neuroprotective effects through:\n\n- Anti-apoptotic signaling\n- Protection against oxidative stress\n- Regulation of autophagy\n\n---\n\n## Prion Diseases\n\n### Disease Spectrum\n\nPrion diseases can be acquired through infection, inherited through mutations in PRNP, or arise sporadically [@Belay1999][@Geschwind2015]:\n\n1. **Sporadic Creutzfeldt-Jakob Disease (sCJD)**: Most common form (~85% of cases), unknown etiology\n2. **Inherited Prion Diseases**: Caused by PRNP mutations (e.g., P102L, D178N, E200K) that predispose to spontaneous conversion\n3. **Variant CJD (vCJD)**: Acquired from BSE-contaminated food products\n4. **Kuru**: Acquired through ritualistic cannibalism\n5. **Fatal Familial Insomnia (FFI)**: Characterized by progressive insomnia and autonomic dysfunction\n\n### Pathogenesis\n\nPrP^Sc accumulation in the brain leads to:\n\n- **Spongiform degeneration**: Vacuolation of brain tissue\n- **Neuronal loss**: Progressive death of neurons\n- **Gliosis**: Activation of astrocytes and microglia\n- **Amyloid plaque formation**: In some variants\n\nThe neurotoxicity of PrP^Sc appears to involve disruption of synaptic function, induction of endoplasmic reticulum stress, and activation of apoptotic pathways [@Colby2010][@Caughey2009].\n\n### Genetic Susceptibility\n\nPolymorphisms at codon 129 of PRNP (methionine or valine) strongly influence disease susceptibility and phenotype:\n\n- 129M/M: Predisposes to vCJD and certain CJD subtypes\n- 129V/V: Associated with longer incubation times\n- Heterozygosity may provide some protection\n\n---\n\n## Relationship to Alzheimer's Disease\n\nInteresting connections between PrP and AD have emerged [@Watts2014]:\n\n### PrP as an Aβ Receptor\n\nPrP can bind amyloid-beta peptides and may function as a receptor mediating Aβ-induced synaptic dysfunction. This interaction may:\n\n- Facilitate Aβ toxicity at synapses\n- Activate downstream signaling pathways\n- Contribute to early synaptic impairment in AD\n\n### Shared Mechanisms\n\nBoth prion diseases and AD involve:\n\n- Protein misfolding and aggregation\n- Synaptic loss\n- Progressive neurodegeneration\n- spreading through brain networks\n\n### Therapeutic Implications\n\nUnderstanding the intersection of PrP and AD pathology may reveal novel therapeutic targets for both conditions.\n\n### Molecular Mechanisms of PrP-Aβ Interaction\n\n**Binding Sites:**\n- The Aβ binding region on PrP is located in the N-terminal domain\n- Specific amino acids (including glutamine and asparagine residues) facilitate Aβ binding\n- The interaction is thought to be largely hydrophobic with some electrostatic components\n\n**Downstream Signaling:**\n- PrP-Aβ binding activates Fyn kinase\n- Leads to NMDA receptor phosphorylation\n- Results in excitotoxic calcium influx\n- Triggers downstream apoptotic pathways\n\n**Synaptic Effects:**\n- PrP mediates Aβ-induced synaptic spine loss\n- Impairs long-term potentiation (LTP)\n- Disrupts synaptic plasticity mechanisms\n- Contributes to early cognitive deficits\n\n### PrP in Other Neurodegenerative Diseases\n\n**Parkinson's Disease:**\n- PrP may interact with alpha-synuclein\n- Potential role in Lewy body formation\n- Possible influence on dopaminergic neuron survival\n\n**Huntington's Disease:**\n- PrP expression altered in HD models\n- May interact with mutant huntingtin\n- Potential contribution to synaptic dysfunction\n\n**Amyotrophic Lateral Sclerosis:**\n- PrP implicated in TDP-43 proteinopathy\n- Potential role in motor neuron vulnerability\n- May influence disease progression\n\n### PrP and Neuroinflammation\n\n**Microglial Activation:**\n- PrP can be released from neurons in exosomes\n- Extracellular PrP may activate microglia\n- Contributes to chronic neuroinflammation\n- Creates feedback loop promoting neurodegeneration\n\n**Cytokine Regulation:**\n- PrP influences cytokine production\n- Modulates inflammatory responses\n- May both promote and suppress inflammation depending on context\n\n**Blood-Brain Barrier:**\n- PrP affects BBB integrity\n- Dysregulation may allow peripheral immune cell entry\n- Contributes to neuroinflammatory processes\n\n### Cellular PrP Functions\n\n**Protein Quality Control:**\n- PrP interacts with cellular quality control machinery\n- May help target misfolded proteins for degradation\n- Loss of PrP function may impair protein clearance\n\n**Metal Ion Homeostasis:**\n- Copper binding is well-characterized\n- PrP may also bind other metal ions (zinc, iron)\n- Metal dyshomeostasis is implicated in multiple neurodegenerative diseases\n\n**Cell Adhesion:**\n- PrP functions as a cell adhesion molecule\n- Mediates cell-cell interactions at synapses\n- Influences neuronal connectivity during development\n\n### PrP in Aging and Cellular Senescence\n\n**Age-Related Changes:**\n- PrP expression changes with age\n- Oxidative modifications accumulate\n- May contribute to age-related neuronal vulnerability\n\n**Cellular Senescence:**\n- PrP may influence cellular senescence pathways\n- Senescent neurons show altered PrP expression\n- Could contribute to age-related neurodegeneration\n\n### PrP Spread and Propagation\n\n**Prion-Like Mechanisms:**\n- Aβ and tau can propagate via prion-like mechanisms\n- PrP may facilitate this spread\n- Template-driven misfolding in other proteins\n\n**Tissue-Specific Vulnerability:**\n- Neurons with high PrP expression are more vulnerable\n- Different brain regions show varying susceptibility\n- Regional PrP levels influence disease patterns\n\n### Biomarkers and Diagnostic Applications\n\n**Fluid Biomarkers:**\n- CSF PrP levels as potential biomarker\n- 14-3-3 protein in CSF for CJD diagnosis\n- Tau and neurofilament light chain measurements\n\n**Imaging Biomarkers:**\n- PET ligands for PrP aggregates\n- MRI for detecting spongiform changes\n- Diffusion tensor imaging for connectivity changes\n\n**Genetic Markers:**\n- PRNP polymorphisms modify disease risk\n- Codon 129 influences sporadic CJD\n- Octapeptide repeat number variations\n\n## Therapeutic Strategies\n\n### Current Approaches\n\nNo effective disease-modifying therapies exist for prion diseases. Strategies under investigation include [@Aguib2022][@Johnson2005][@Caughey2009]:\n\n1. **Anti-prion compounds**: Small molecules that stabilize PrP^C or inhibit PrP^Sc formation\n2. **Immunotherapy**: Antibodies targeting PrP^Sc or preventing conversion\n3. **Gene silencing**: siRNA or antisense oligonucleotides to reduce PrP expression\n4. **Symptomatic treatment**: Managing cognitive and behavioral symptoms\n\n### Challenges\n\n- The blood-brain barrier limits drug delivery\n- PrP^Sc exists in multiple strains with distinct properties\n- Intervention must occur early in disease course\n- Need for reliable biomarkers to guide treatment\n- Heterogeneity of clinical presentations complicates diagnosis\n\n---\n\n## Specific Prion Disease Types\n\n### Sporadic Creutzfeldt-Jakob Disease (sCJD)\n\nsCJD represents approximately 85% of all human prion disease cases:\n\n**Epidemiology**\n- Incidence: 1-2 per million annually worldwide\n- Typically presents in individuals 50-70 years of age\n- Slight male predominance in some populations\n\n**Clinical Features**\n- Rapidly progressive dementia\n- Ataxia and cerebellar signs\n- Myoclonus (especially startle-induced)\n- Visual disturbances including cortical blindness\n- Pyramidal and extrapyramidal signs\n- Akinetic mutism in late stages\n\n**Subtypes**\n- MM1/MV1: Most common, rapid progression\n- VV2: Cerebellar predominant, slower progression\n- MM2: Longer disease duration\n\n**Diagnostic Features**\n- 14-3-3 protein in cerebrospinal fluid\n- Periodic sharp wave complexes on EEG\n- MRI hyperintensities in cortex and basal ganglia\n- Real-time quaking-induced conversion (RT-QuIC) positive\n\n### Variant Creutzfeldt-Jakob Disease (vCJD)\n\nvCJD results from exposure to bovine spongiform encephalopathy (BSE):\n\n**Epidemiology**\n- Linked to consumption of BSE-contaminated beef\n- First described in 1996 in the United Kingdom\n- Approximately 230 cases worldwide\n\n**Clinical Features**\n- Psychiatric symptoms at onset (depression, anxiety)\n- Behavioral changes and personality alterations\n- Sensory abnormalities including dysesthesia\n- Ataxia developing later in disease course\n- Progressive dementia\n- Longer survival than sCJD (median 14-18 months)\n\n**Pathological Features**\n- PrP amyloid plaques (florid plaques) throughout brain\n- PrP deposition in lymphoid tissues\n- Spongiform changes in basal ganglia and cerebellum\n\n### Fatal Familial Insomnia (FFI)\n\nFFI represents a unique prion disease with predominant sleep dysfunction:\n\n**Genetic Basis**\n- Caused by PRNP mutation D178N with methionine at codon 129\n- Autosomal dominant inheritance\n- Incomplete penetrance depending on codon 129 genotype\n\n**Clinical Features**\n- Progressive insomnia\n- Autonomic dysfunction (hyperhidrosis, hypertension)\n- Dysphagia and weight loss\n- Cognitive decline in later stages\n- Visual and auditory hallucinations\n\n**Neuropathology**\n- Selective thalamic degeneration, especially dorsomedial nucleus\n- Minimal spongiform change\n- PrP deposition in thalamus and inferior olive\n\n### Gerstmann-Sträussler-Scheinker Syndrome (GSS)\n\nGSS is a rare inherited prion disease:\n\n**Genetic Basis**\n- PRNP mutations including P102L, A117V, F198I, Q217R\n- Autosomal dominant inheritance\n- Variable age of onset (35-55 years typically)\n\n**Clinical Features**\n- Progressive ataxia\n- Dementia (later onset than ataxia)\n- Pyramidal signs\n- Extrapyramidal features in some subtypes\n- Disease duration: 2-10 years\n\n**Pathological Features**\n- PrP amyloid plaques throughout cerebellum and cerebral cortex\n- Multicentric plaque formation\n- Spongiform changes variable\n\n### Iatrogenic Prion Disease\n\nTransmission through medical procedures includes:\n\n**Sources of Transmission**\n- Dura mater grafts (historical)\n- Corneal transplants\n- Human growth hormone (historical)\n- Gonadotropin hormone\n- Blood transfusion (rare cases)\n\n**Clinical Features**\n- Similar to sCJD but longer incubation periods\n- For growth hormone cases: 5-20 year incubation\n- Typically rapid progression once symptomatic\n\n---\n\n## Cellular and Molecular Mechanisms\n\n### PrP^Sc Conversion Mechanism\n\nThe conversion of PrP^C to PrP^Sc involves:\n\n**Template-Directed Conversion**\n- PrP^Sc serves as template for conversion of PrP^C\n- Conformational information transfer through direct interaction\n- Heterodimer formation as intermediate\n\n**Nucleation-Dependent Polymerization**\n- PrP^Sc aggregates form through seeded polymerization\n- Lag phase followed by exponential growth\n- Fibril elongation through addition of monomers\n\n**Structural Transition**\n- Loss of α-helical content (from 40% to 20%)\n- Increase in β-sheet structure (from 10% to 40%)\n- Domain rearrangement in C-terminal region\n\n### PrP^Sc Strain Diversity\n\nPrion strains represent different conformations:\n\n**Strain Characteristics**\n- Distinct physicochemical properties\n- Different incubation periods in hosts\n- Variable neuropathology\n- Differential protease resistance patterns\n\n**Mechanisms of Strain Variation**\n- Different folding patterns of PrP^Sc\n- Variations in aggregation state\n- Distinct protofibril structures\n\n### Cellular Toxicity Pathways\n\nPrP^Sc causes neurotoxicity through multiple mechanisms:\n\n**ER Stress**\n- Accumulation of misfolded proteins triggers unfolded protein response\n- CHOP-mediated apoptosis\n- Disruption of calcium homeostasis\n\n**Oxidative Stress**\n- Mitochondrial dysfunction\n- Increased reactive oxygen species\n- Lipid peroxidation\n- DNA damage\n\n**Synaptic Dysfunction**\n- Loss of synaptic proteins\n- Impaired neurotransmitter release\n- Disruption of synaptic plasticity\n- Calcium dysregulation\n\n**Glial Activation**\n- Microglial activation and inflammation\n- Astrocyte reactivity\n- Cytokine release\n- Neuroinflammation amplification\n\n---\n\n## PrP and Other Neurodegenerative Diseases\n\n### PrP in Parkinson's Disease\n\nConnections between PrP and PD include:\n\n- PrP expression in dopaminergic neurons\n- Potential interaction with α-synuclein\n- Role in metal homeostasis relevant to PD\n- Possible common pathways in protein aggregation\n\n### PrP and Amyotrophic Lateral Sclerosis\n\nALS shares features with prion diseases:\n\n- PrP deposition in some ALS cases\n- Common mechanisms of protein aggregation\n- Overlapping pathways of cellular stress\n\n### Metal Ion Homeostasis\n\nPrP interacts with various metal ions:\n\n**Copper**\n- High affinity binding to octapeptide repeats\n- Role in copper uptake and distribution\n- Antioxidant function through SOD-like activity\n- Dyshomeostasis in prion disease\n\n**Iron**\n- PrP affects iron metabolism\n- Iron dysregulation in prion disease\n- Possible role in oxidative stress\n\n**Zinc**\n- PrP-zinc interactions\n- Potential signaling functions\n\n---\n\n## PrP as a Therapeutic Target\n\n### Immunotherapeutic Approaches\n\n**Active Immunization**\n- Vaccines targeting PrP^Sc\n- Generation of anti-PrP antibodies\n- Challenges: overcoming immune tolerance\n- Clinical trials in animal models\n\n**Passive Immunization**\n- Administration of anti-PrP monoclonal antibodies\n- Examples: 6D11, 8H4, Prioclone\n- Delivery challenges across blood-brain barrier\n\n### Small Molecule Inhibitors\n\n**Polyanionic Compounds**\n- Sulfated glycans inhibit PrP conversion\n- Pentosan polysulfate in clinical use\n- Limitations: poor BBB penetration\n\n**Tetracycline Derivatives**\n- Doxycycline shows anti-prion activity\n- Binding to PrP^Sc prevents aggregation\n- Clinical trials ongoing\n\n**Metal Chelators**\n- Cu/Zn chelation reduces conversion\n- Clioquinol trials in prion disease\n\n### Gene Silencing Approaches\n\n**Antisense Oligonucleotides**\n- Target PRNP mRNA\n- Reduce PrP^C expression\n- ASO trials in development\n- Advantages: specificity, distribution\n\n**RNAi Approaches**\n- siRNA targeting PRNP\n- Viral vector delivery\n- Challenges: efficient CNS delivery\n\n### Protein-Based Therapies\n\n**Dominant-Negative PrP**\n- Expression of mutant PrP that interferes with conversion\n- Competitive inhibition of PrP^Sc formation\n- Proof-of-concept in cell models\n\n**Chaperone-Based Approaches**\n- Heat shock proteins in PrP metabolism\n- Enhancement of PrP^C folding\n- Targeting protein quality control\n\n---\n\n## Diagnostic Biomarkers\n\n### Current Biomarkers\n\n**Cerebrospinal Fluid Markers**\n- 14-3-3 protein: sensitivity ~95%, specificity ~40%\n- Tau protein: elevated in some cases\n- Neurofilament light chain: promising marker\n\n**Real-Time Quaking-Induced Conversion (RT-QuIC)**\n- Sensitivity: 80-90% for sCJD\n- Specificity: >95%\n- Detects PrP^Sc seeding activity\n- Applied to CSF, olfactory epithelium, skin\n\n### Emerging Biomarkers\n\n**Blood-Based Markers**\n- PrP detection in plasma\n- Exosome-associated PrP^Sc\n- Sensitive detection methods in development\n\n**Imaging Biomarkers**\n- PET ligands for PrP^Sc\n- MRI advanced techniques\n- Diffusion tensor imaging\n\n---\n\n## Brain Atlas Resources\n\n- **Allen Human Brain Atlas**: [PRNP expression search](https://human.brain-map.org/microarray/search/show?search_term=PRNP)\n- **Allen Mouse Brain Atlas**: [Prnp search](https://mouse.brain-map.org/search/index.html?query=Prnp)\n- **BrainSpan Developmental Transcriptome**: [PRNP developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PRNP)\n\n### Clinical Trials and Emerging Therapies\n\n**Anti-Prion Compounds in Development:**\n- Polyanionic compounds that stabilize PrP^C\n- Small molecules targeting PrP^Sc formation\n- Natural products with anti-prion activity\n\n**Immunotherapy Approaches:**\n- Active immunization with PrP antigens\n- Passive monoclonal antibody administration\n- Antibody fragments for better brain penetration\n- CAR-T cell approaches for prion clearance\n\n**Gene Therapy Strategies:**\n- PRNP knockdown using RNAi approaches\n- CRISPR-based gene editing for correction\n- PRNP expression modulation\n- Viral vector-mediated delivery of anti-prion constructs\n\n**Combination Therapies:**\n- Antibody plus small molecule combinations\n- Gene therapy with pharmacological adjuncts\n- Multi-target approaches for maximum effect\n\n### Protein Dynamics and Misfolding\n\n**Folding Pathways:**\n- PrP folding occurs in the endoplasmic reticulum\n- Misfolding can occur at multiple stages\n- Quality control mechanisms normally prevent accumulation\n- Failure of quality control leads to disease\n\n**Aggregation Mechanisms:**\n- Nucleation-dependent polymerization\n- Formation of oligomeric intermediates\n- Amyloid fibril assembly\n- Strain variation through different conformations\n\n**Cellular Quality Control:**\n- ER-associated degradation (ERAD)\n- Autophagy-lysosome pathway\n- Proteasome-mediated degradation\n- Unfolded protein response activation\n\n### PrP in Prion Disease Subtypes\n\n**Sporadic CJD (sCJD):**\n- Most common form (~85% of cases)\n- No known genetic or infectious cause\n- Likely spontaneous PrP^Sc formation\n- Variable clinical presentation based on PRNP genotype\n\n**Variant CJD (vCJD):**\n- Acquired from BSE exposure\n- Younger age of onset than sCJD\n- Prominent psychiatric features\n- Long incubation period\n\n**Iatrogenic CJD:**\n- Transmission through medical procedures\n- corneal transplants, dura mater grafts\n- Contaminated human growth hormone\n- Blood transfusion transmission documented\n\n**Fatal Familial Insomnia (FFI):**\n- PRNP D178N mutation with methionine at codon 129\n- Primary insomnia with autonomic dysfunction\n- Selective thalamic degeneration\n- Distinct clinical phenotype from CJD\n\n### PrP Structural Biology\n\n**X-ray Crystallography:**\n- Detailed structure of C-terminal domain\n- Insight into helix-turn-helix arrangement\n- Domain organization in the structured region\n\n**NMR Studies:**\n- Dynamics of N-terminal domain\n- Flexible regions in physiological conditions\n- Conformational changes upon misfolding\n\n**Cryo-EM:**\n- Amyloid fibril structures\n- Different prion strain conformations\n- Polymorphic fibril architectures\n\n### PrP in Neurodevelopment\n\n**Developmental Expression:**\n- High expression during embryogenesis\n- Peak levels in early postnatal period\n- Sustained expression in adult brain\n- Cell type-specific patterns\n\n**Developmental Functions:**\n- Neuronal differentiation\n- Synapse formation\n- Myelination\n- Astrocyte maturation\n\n**Knockout Phenotypes:**\n- Relatively mild phenotype in Prnp-/- mice\n- Compensatory mechanisms exist\n- Subtle neurological deficits in specific contexts\n\n### Research Methods\n\n**Biochemical Approaches:**\n- Western blotting for PrP detection\n- ELISA for quantification\n- Pulse-chase experiments for trafficking\n- Proteomics for interaction mapping\n\n**Cell Biology:**\n- Cell culture models (neurons, astrocytes)\n- Primary neuronal cultures\n- Stem cell-derived neurons\n- Live cell imaging\n\n**Animal Models:**\n- Mouse models of prion disease\n- Transgenic mice expressing mutant PRNP\n- Knock-in models with human PRNP\n- Zebrafish models for development\n\n**Structural Methods:**\n- X-ray crystallography\n- NMR spectroscopy\n- Cryo-electron microscopy\n- Mass spectrometry\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n- [Prion Diseases](/diseases/prion-diseases)\n- [PRNP Gene](/genes/prnp)\n- [Amyloid-beta Protein](/proteins/amyloid-beta)\n- [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)\n- [Synaptic Dysfunction](/mechanisms/synaptic-failure-pathway)\n\n---\n\n## External Links\n\n- **UniProt**: [P04156 - PRNP](https://www.uniprot.org/uniprotkb/P04156)\n- **AlphaFold**: [PrP Structure Prediction](https://alphafold.ebi.ac.uk/entry/P04156)\n- **OMIM**: [176640 - PRNP](https://omim.org/entry/176640)\n- **GeneCards**: [PRNP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRNP)\n- **PubMed**: [Prion protein literature](https://pubmed.ncbi.nlm.nih.gov/?term=prion+protein+PRNP)\n- **Human Protein Atlas**: [PRNP expression](https://www.proteinatlas.org/ENSG00000161133-PRNP)\n- **STRING Database**: [PrP interaction network](https://string-db.org/)\n\n### Prion Disease Surveillance and Public Health\n\n**Global Surveillance Networks:**\n- National CJD surveillance systems\n- WHO collaborative surveillance\n- Rapid alert systems for new variants\n\n**BSE and Food Safety:**\n- Cattle testing protocols\n- Feed restrictions and controls\n- Human exposure risk assessment\n\n**Infection Control:**\n- Sterilization protocols for surgical equipment\n- Blood donor screening\n- Tissue transplantation safety\n\n### PrP and Copper Metabolism Connection\n\n**Copper Binding Properties:**\n- High affinity binding to octapeptide repeats\n- Different affinity for Cu(I) and Cu(II)\n- Multiple binding sites per PrP molecule\n\n**Copper Transport:**\n- PrP may function as copper receptor\n- Facilitates copper uptake into cells\n- Participates in cellular copper distribution\n\n**Implications for Disease:**\n- Copper dyshomeostasis in prion disease\n- Potential therapeutic targeting of copper pathways\n- Interaction with other neurodegenerative processes\n\n### PrP and Zinc Metabolism\n\n**Zinc Binding:**\n- PrP can bind zinc ions\n- Different binding site than copper\n- Modulates PrP aggregation properties\n\n**Zinc Signaling:**\n- Important for synaptic function\n- PrP may regulate zinc availability\n- Implications for synaptic plasticity\n\n### PrP in Oligodendrocyte Function\n\n**Myelin Maintenance:**\n- PrP expressed in oligodendrocytes\n- Important for myelin integrity\n- Dysfunction may contribute to demyelination\n\n**White Matter Pathology:**\n- White matter changes in CJD\n- Potential for therapeutic intervention\n- Imaging biomarkers for progression\n\n### PrP in Astrocyte Function\n\n**Astrocyte Expression:**\n- PrP expressed in astrocytes\n- Functions in astrocyte-neuron communication\n- May influence neurovascular unit\n\n**Reactive Astrocytosis:**\n- Astrocyte activation in prion disease\n- Both protective and harmful roles\n- Potential therapeutic target\n\n### PrP and Blood-Brain Barrier\n\n**BBB Regulation:**\n- PrP influences BBB development\n- Maintains BBB integrity\n- Dysfunction allows peripheral access\n\n**Therapeutic Implications:**\n- Drug delivery challenges\n- Strategies to improve brain penetration\n- Engineering of therapeutic antibodies\n\n### Genetic Epidemiology\n\n**Population Studies:**\n- Allele frequency variations\n- Founder mutations in specific populations\n- Consanguinity effects on incidence\n\n**Genotype-Phenotype Correlations:**\n- 129 polymorphism effects\n- Mutation-specific clinical presentations\n- Modifier genes and modifiers\n\n### PrP in Veterinary Medicine\n\n**Animal Prion Diseases:**\n- Scrapie in sheep and goats\n- BSE in cattle\n- Chronic wasting disease in cervids\n- Feline spongiform encephalopathy\n\n**Zoonotic Potential:**\n- Species barrier studies\n- Cross-species transmission\n- Public health implications\n\n### Future Research Directions\n\n**Basic Science Priorities:**\n- Structural basis for strain variation\n- Molecular mechanisms of neurotoxicity\n- Early diagnostic markers\n\n**Clinical Priorities:**\n- Disease-modifying therapies\n- Biomarkers for clinical trials\n- Early intervention strategies\n\n**Therapeutic Priorities:**\n- Small molecule development\n- Antibody therapeutics\n- Gene therapy approaches\n- Combination therapies\n\n---\n\n## References\n\n1. [Linden, Biology of the prion protein (2024)](https://doi.org/10.1016/j.sbi.2024.101527)\n2. [Watzlawik, Prion protein: structure and function (2023)](https://doi.org/10.1016/bs.pmbts.2023.02.001)\n3. [Caughey, Prion protein conversions (2023)](https://doi.org/10.1038/s41579-022-00771-4)\n4. [Aguib, Prion protein therapeutics (2022)](https://doi.org/10.1038/s41582-022-00635-8)\n5. [Prusiner, Prions (2015)](https://doi.org/10.1073/pnas.1514714112)\n6. [Caughey, Prion protein conversion in vitro (2014)](https://doi.org/10.1016/j.jmb.2014.02.009)\n7. [Soto, Prions: the biological particles that transmit neurodegenerative diseases (2011)](https://doi.org/10.4161/pri.5.3.16574)\n8. [Collins, Molecular genetics of human prion diseases (2001)]([DOI:10.1016/S0361-9230(01)00643-2](https://doi.org/10.1016/S0361-9230(01)00643-2))\n9. [Colby, Prions: propagation and evolution (2010)](https://doi.org/10.1007/82_2010_106)\n10. [Caughey, Prions and their potential therapeutic targeting (2009)](https://doi.org/10.2741/3376)\n11. [Soto, Challenges for prion disease diagnostics (2010)](https://doi.org/10.1007/s00018-010-0270-5)\n12. [Belay, Human prion diseases (1999)](https://doi.org/10.1128/CMR.12.2.281)\n13. [Johnson, Therapeutic approaches to prion disease (2005)](https://doi.org/10.1385/1-59259-848-3:331)\n14. [Caughey, Trends in prion biology and disease (2011)](https://doi.org/10.1042/ETLS20170039)\n15. [Geschwind, Prion diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25634165/)\n16. [Zanusso, Prion protein structural features and pathological isoforms (2016)](https://pubmed.ncbi.nlm.nih.gov/27689081/)\n17. [Purro, Prions and synaptic dysfunction (2012)](https://doi.org/10.4161/pri.20245)\n18. [Watts, Prion protein and Alzheimer disease: the end of the beginning? (2014)]([DOI:10.1016/S1474-4422(14)70158-1](https://doi.org/10.1016/S1474-4422(14)70158-1))\n19. [Bellinger, Prions in the brain and neurodegenerative disease (2015)](https://doi.org/10.1007/s11064-015-1577-2)\n20. [Soto, Functional role of the cellular prion protein in health and disease (2013)](https://doi.org/10.2217/fnl.13.42)\n21. [Hill et al., Prion disease diagnosis and RT-QuIC (2023)](https://pubmed.ncbi.nlm.nih.gov/37015345/)\n22. [Chen et al., Prion protein and metal ion homeostasis (2022)](https://doi.org/10.1016/j.ccr.2022.214891)\n23. [Biasini et al., Cellular prion protein and neuronal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)",
  "entity_type": "protein"
}